{"id":"tazemetostat","rwe":[{"pmid":"41898517","year":"2026","title":"Biological Evaluation of a Novel Compound with Predicted EZH2 and EED Binding Against Human Malignant Melanoma Cells.","finding":"","journal":"International journal of molecular sciences","studyType":"Clinical Study"},{"pmid":"41882006","year":"2026","title":"Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study.","finding":"","journal":"Nature communications","studyType":"Clinical Study"},{"pmid":"41874585","year":"2026","title":"Epithelioid sarcoma: from SMARCB1 loss to therapeutic vulnerabilities.","finding":"","journal":"Current opinion in oncology","studyType":"Clinical Study"},{"pmid":"41744650","year":"2026","title":"EZH2 Inhibition Restores Tumor Suppressor SFRP1 Activity by Reprogramming Extrachromosomal Circular DNA Dynamics in Ovarian Cancer.","finding":"","journal":"Biology","studyType":"Clinical Study"},{"pmid":"41736412","year":"2026","title":"Therapeutic Horizons in Targeting EZH2 With Dual and Non-PROTAC Inhibitor Molecules: Recent Achievements, Comparative Analysis, and Future Perspectives.","finding":"","journal":"Archiv der Pharmazie","studyType":"Clinical Study"}],"_fda":{"id":"8685c0e3-065c-4c2e-bd99-16c51c3a4739","set_id":"7db07b5f-4e22-467c-9c0a-f830b08dbb1d","openfda":{"unii":["6P89T5M073"],"route":["ORAL"],"rxcui":["2274384","2274390"],"spl_id":["8685c0e3-065c-4c2e-bd99-16c51c3a4739"],"brand_name":["TAZVERIK"],"spl_set_id":["7db07b5f-4e22-467c-9c0a-f830b08dbb1d"],"package_ndc":["72607-100-00"],"product_ndc":["72607-100"],"generic_name":["TAZEMETOSTAT"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["TAZEMETOSTAT HYDROBROMIDE"],"manufacturer_name":["Epizyme, Inc."],"application_number":["NDA211723"],"is_original_packager":[true]},"version":"8","pregnancy":["8.1 Pregnancy Risk Summary Based on findings from animal studies and its mechanism of action [see Clinical Pharmacology ( 12.1 )] , TAZVERIK can cause fetal harm when administered to pregnant women. There are no available data on TAZVERIK use in pregnant women to inform the drug-associated risk. Administration of tazemetostat to pregnant rats and rabbits during organogenesis resulted in dose-dependent increases in skeletal developmental abnormalities in both species beginning at maternal exposures approximately 1.5 times the adult human exposure [AUC 0-45h ] at the 800 mg twice daily dose (see Data ) . Advise pregnant women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In pregnant rats, once daily oral administration of tazemetostat during the period of organogenesis from gestation day (GD) 7 through 17 resulted in no maternal adverse effects at doses up to 100 mg/kg/day (approximately 6 times the adult human exposure at 800 mg twice daily). Skeletal malformations and variations occurred in fetuses at doses of ≥50 mg/kg (approximately 2 times the adult human exposure at the 800 mg twice daily dose). At 200 mg/kg (approximately 14 times the adult human exposure at the 800 mg twice daily dose), major findings included increased post implantation loss, missing digits, fused vertebrae, domed heads and fused bones of the skull, and reduced fetal body weights. In pregnant rabbits, no adverse maternal effects were observed after once daily oral administration of 400 mg/kg/day tazemetostat (approximately 7 times the adult human exposure at the 800 mg twice daily dose) from GD 7 through 19. Skeletal variations were present at doses ≥100 mg/kg/day (approximately 1.5 times the adult human exposure at the 800 mg twice daily dose), with skeletal malformations at ≥200 mg/kg/day (approximately 5.6 times the adult human exposure at the 800 mg twice daily dose). At 400 mg/kg (approximately 7 times the adult human exposure at the 800 mg twice daily dose), major findings included increased post implantation loss and cleft palate and snout."],"references":["15 REFERENCES Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586."],"description":["11 DESCRIPTION Tazemetostat is a methyltransferase inhibitor. Tazemetostat hydrobromide has the following chemical name: [1,1'-Biphenyl]-3-carboxamide, N -[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2 H -pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-, hydrobromide (1:1). The molecular formula of tazemetostat hydrobromide is C 34 H 44 N 4 O 4 ∙HBr. Tazemetostat hydrobromide has a molecular weight of 653.66 g/mol and the following structural formula: Tazemetostat hydrobromide is a white to off-white solid that is slightly soluble in water and has pKa values of 5.26, 6.88, and 12.62. A saturated aqueous solution of tazemetostat hydrobromide has a pH of approximately 5 at ambient conditions. TAZVERIK (tazemetostat) tablets for oral use contain 200 mg tazemetostat, equivalent to 228 mg tazemetostat hydrobromide. Each tablet is film-coated and contains the following inactive ingredients in the tablet core: hydroxypropyl cellulose, lactose monohydrate, low-substituted hydroxypropyl cellulose, magnesium stearate, and sodium starch glycolate. The film-coat contains hypromellose, polyethylene glycol, red iron oxide, talc, and titanium dioxide. Structural Formula"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING TAZVERIK 200 mg film-coated tablets are red, round, biconvex shape and debossed with \"EZM 200\" on one side and plain on the other. TAZVERIK is available in: Bottles of 240 tablets with a desiccant; NDC 72607-100-00 Do not store above 30°C (86°F)."],"spl_medguide":["This Medication Guide has been approved by the U.S. Food and Drug Administration. Issued: November/2023 MEDICATION GUIDE TAZVERIK ® (taz vayr′ ik) (tazemetostat) tablets What is the most important information I should know about TAZVERIK? TAZVERIK can cause serious side effects, including: Risk of new cancers. An increase in new (second) cancers has happened in people who were treated with TAZVERIK. Talk with your healthcare provider about your risk of developing new cancers. Your healthcare provider will monitor you for new cancers after your treatment with TAZVERIK. Tell your healthcare provider if you are more tired than usual, or have easy bruising, fever, bone pain, or paleness. See \" What are the possible side effects of TAZVERIK \" for more information about side effects. What is TAZVERIK? TAZVERIK is a prescription medicine used to treat: adults and children aged 16 years and older with epithelioid sarcoma that has spread or grown and cannot be removed by surgery. adults with follicular lymphoma when the disease has come back or did not respond to treatment, whose tumors have an abnormal EZH2 gene, and who have been treated with at least two prior medicines. Your healthcare provider will perform a test to make sure TAZVERIK is right for you. adults with follicular lymphoma when the disease has come back or did not respond to treatment, who have no other satisfactory treatment options. It is not known if TAZVERIK is safe and effective in children less than 16 years of age. Before taking TAZVERIK tell your healthcare provider about all of your medical conditions, including if you: are pregnant or plan to become pregnant. TAZVERIK can harm your unborn baby. Your healthcare provider will give you a pregnancy test before you start treatment with TAZVERIK. Tell your healthcare provider right away if you become pregnant or think you may be pregnant. Females who are able to become pregnant should use effective non-hormonal birth control (such as condoms) during treatment and for 6 months after the final dose of TAZVERIK. Birth control pills (oral contraceptives) and other hormonal forms of birth control may not be effective if used during treatment with TAZVERIK. Talk to your healthcare provider about birth control options that are right for you. Males with female partners who are able to become pregnant should use effective birth control during treatment and for 3 months after the final dose of TAZVERIK. are breastfeeding or plan to breastfeed. It is not known if TAZVERIK passes into your breast milk. Do not breastfeed during treatment and for 1 week after the final dose of TAZVERIK. Tell your healthcare provider about all the medicines you take , including prescription and over-the-counter medicines, vitamins, and herbal supplements. TAZVERIK may affect the way other medicines work and other medicines may affect how TAZVERIK works. How should I take TAZVERIK? Take TAZVERIK exactly as your healthcare provider tells you. Take TAZVERIK 2 times each day. Take TAZVERIK with or without food. Swallow TAZVERIK tablets whole. Do not cut, crush, or chew tablets. If you miss a dose or vomit after taking your dose, just skip that dose and take the next dose at your regular time. Your healthcare provider may change your dose, temporarily stop, or completely stop treatment with TAZVERIK if you get certain side effects. What should I avoid while taking TAZVERIK? Avoid eating grapefruit or drinking grapefruit juice during treatment with TAZVERIK. Avoid taking St. John's wort during treatment with TAZVERIK. What are the possible side effects of TAZVERIK? TAZVERIK can cause serious side effects. See \"What is the most important information I should know about TAZVERIK?\" The most common side effects of TAZVERIK in people with epithelioid sarcoma include: pain nausea vomiting tiredness decreased appetite constipation The most common side effects of TAZVERIK in people with follicular lymphoma include: tiredness bone and muscle pain cold-like symptoms (upper respiratory infection) nausea stomach (abdominal) pain These are not all the possible side effects of TAZVERIK. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store TAZVERIK? Do not store TAZVERIK tablets above 86°F (30°C). Keep TAZVERIK and all medicines out of the reach of children. General information about the safe and effective use of TAZVERIK. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use TAZVERIK for a condition for which it was not prescribed. Do not give TAZVERIK to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about TAZVERIK that is written for health professionals. What are the ingredients in TAZVERIK? Active Ingredient: tazemetostat. Inactive Ingredients: Tablet core: hydroxypropyl cellulose, lactose monohydrate, low-substituted hydroxypropyl cellulose, magnesium stearate, and sodium starch glycolate. Film-coating: hypromellose, polyethylene glycol, red iron oxide, talc, and titanium dioxide. Manufactured for: Epizyme, Inc. An Ipsen Company One Main St. Cambridge, MA 02142 For more information, contact Epizyme at 855-463-5127."],"geriatric_use":["8.5 Geriatric Use Clinical studies of TAZVERIK did not include sufficient numbers of patients with epithelioid sarcoma or relapsed or refractory follicular lymphoma aged 65 and over to determine whether they respond differently from younger subjects."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of TAZVERIK have been established in pediatric patients aged 16 years and older (adolescents) with metastatic or locally advanced epithelioid sarcoma. Use of TAZVERIK for this indication is supported by evidence from adequate and well-controlled studies in adults (including 3 adolescent patients aged 16 years) [see Adverse Reactions ( 6.1 ), Clinical Pharmacology ( 12.3 ), Clinical Studies ( 14.1 )] . The safety and effectiveness of TAZVERIK in pediatric patients aged less than 16 years have not been established. Juvenile Animal Toxicity Data In a 13-week juvenile rat toxicology study, animals were dosed daily from post-natal day 7 to day 97 (approximately equivalent to neonate to adulthood). Tazemetostat resulted in: T-LBL at doses ≥50 mg/kg (approximately 2.8 times the adult human exposure at the 800 mg twice daily dose) Increased trabecular bone at doses ≥100 mg/kg (approximately 10 times the adult human exposure at the 800 mg twice daily dose) Increased body weight at doses ≥50 mg/kg (approximately equal to the adult human exposure at the 800 mg twice daily dose) Distended testicles in males at doses ≥50 mg/kg (approximately equal to the adult human exposure at the 800 mg twice daily dose)"],"effective_time":"20240815","clinical_studies":["14 CLINICAL STUDIES 14.1 Epithelioid Sarcoma The efficacy of TAZVERIK was evaluated in an open-label, single-arm cohort (Cohort 5) of a multi-center study (Study EZH-202, NCT02601950) in patients with histologically confirmed, metastatic or locally advanced epithelioid sarcoma. Patients were required to have INI1 loss, detected using local tests, and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2. Patients received TAZVERIK 800 mg orally twice daily until disease progression or unacceptable toxicity. Tumor response assessments were performed every 8 weeks. The major efficacy outcome measures were confirmed overall response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by blinded independent central review (BICR) and duration of response (DOR). Median duration of follow-up was 14 months (range 0.4 to 31). Among the 62 patients who received TAZVERIK, median age was 34 years (range 16 to 79); 63% were male, 76% were White, 11% were Asian, 44% had proximal disease, 92% had an ECOG PS of 0 or 1, and 8% had an ECOG PS of 2. Prior surgery occurred in 77% of patients; 61% received prior systemic chemotherapy. Efficacy results are summarized in Table 8 . Table 8. Efficacy Results for Patients with Epithelioid Sarcoma Enrolled in Cohort 5 of Study EZH-202 CI = Confidence Interval *Time to response ranged from 1.4 to 18.4 months. Efficacy Endpoints TAZVERIK N=62 Overall Response Rate (95% CI)* 15% (7%, 26%) Complete Response 1.6% Partial Response 13% Duration of Response % with duration ≥ 6 months 67% Range in months 3.7, 24.5+ 14.2 Relapsed or Refractory Follicular Lymphoma The efficacy of TAZVERIK was evaluated in two open-label, single-arm cohorts (Cohorts 4 and 5) of a multi-center study (Study E7438-G000-101, NCT01897571) in patients with histologically confirmed follicular lymphoma after at least 2 prior systemic therapies. Patients were required to have ECOG PS of 0-2 and were enrolled based on EZH2 mutation status. EZH2 mutations were identified prospectively using formalin-fixed, paraffin-embedded tumor samples, which were centrally tested using the cobas ® EZH2 Mutation Test; the cobas EZH2 Mutation test is designed to detect the following mutations: Y646X [S,H,C], Y646F, Y646N, A682G, and A692V. Patients received TAZVERIK 800 mg orally twice daily until confirmed disease progression or unacceptable toxicity. Tumor response assessments were performed every 8 weeks through Week 24 and then every 12 weeks. The major efficacy outcome measures were ORR and DOR according to the International Working Group Non-Hodgkin Lymphoma (IWG-NHL) criteria 1 as assessed by Independent Review Committee. Median duration of follow-up was 22 months (range 3 months to 44 months) for patients with EZH2 MT positive tumors and 36 months (range 32 months to 39 months) for patients whose tumors did not have an EZH2 mutation detected. A total of 99 patients were enrolled, including 45 patients whose tumors had one of these EZH2 mutations (mutant) and 54 patients whose tumors did not have one of these mutations (wild-type). Among the 45 patients with EZH2 mutant follicular lymphoma, median age was 62 years (range 38 to 80), 58% were female, 42% had early progression following front-line therapy (POD24), and all had an ECOG PS of 0 or 1. Race was reported in 84% of patients; of these patients, 82% were White. Based on the cobas EZH2 Mutation test, 36%, 29%, 27%, 11% and 2% of patients had the following mutations: Y646X [S,H,C], Y646F, Y646N, A682G, and A692V, respectively. The median number of lines of prior systemic therapy was 2 (range 1 to 11), with 49% refractory to rituximab, 49% refractory to their last therapy, and 9% had received prior stem cell transplant. Among the 54 patients with EZH2 wild-type follicular lymphoma, median age was 61 years (range 36 to 87), 63% were male, 59% had POD24, and 91% had an ECOG PS of 0 or 1. Race was reported in 57% of patients; of these patients, 48% were White and 3% were Asian. The median number of lines of prior systemic therapy was 3 (range 1 to 8), with 59% refractory to rituximab, 41% refractory to their last therapy, and 39% had received prior stem cell transplant. The approval of TAZVERIK was based upon the efficacy in 95 patients (42 EZH2 Mutant, 53 EZH2 Wild-Type) who had received at least 2 prior systemic therapies and is presented in Table 9 . Table 9. Efficacy Results for Patients with Relapsed or Refractory Follicular Lymphoma Enrolled into Cohorts 4 and 5 of Study E7438-G000-101 CI = Confidence Interval; NE = Not Estimable. *Median time to response for patients with EZH2 MT follicular lymphoma was 3.7 months (range 1.6 to 10.9) and for patients with EZH2 WT follicular lymphoma was 3.9 months (range 1.6 to 16.3). Efficacy Endpoints TAZVERIK N=95 EZH2 Mutant Follicular Lymphoma N=42 EZH2 Wild-Type Follicular Lymphoma N=53 Overall Response Rate (95% CI)* 69% (53%, 82%) 34% (22%, 48%) Complete Response 12% 4% Partial Response 57% 30% Duration of Response Median (95% CI) in months 10.9 (7.2, NE) 13.0 (5.6, NE) Range in months 0.0+, 22.1+ 1, 22.5+"],"pharmacodynamics":["12.2 Pharmacodynamics Tazemetostat exposure-response relationships and the time course of pharmacodynamic responses are unknown. Cardiac Electrophysiology The effect of orally administered TAZVERIK, at doses ranging from 100 mg to 1600 mg twice daily (0.125 to 2 times the approved recommended dosage) for 15 days, on the heart-rate corrected QT (QTc) interval was evaluated in a dose-finding study in 38 patients with advanced malignancies. Tazemetostat and its metabolite EPZ-6930 did not cause a large mean increase (i.e. >20 ms) on the QTc interval at the 800 mg twice daily dose. The largest mean increase (upper bound of 90% confidence interval) in QTc were 6.1 ms (8.5 ms) and 9.3 ms (12.5 ms) at a dose of 800 mg twice daily and 1600 mg twice daily, respectively."],"pharmacokinetics":["12.3 Pharmacokinetics The systemic exposure of tazemetostat is approximately dose proportional over the dose range of 200 mg to 1600 mg twice daily of TAZVERIK (0.25 to 2 times the approved recommended dosage). Following TAZVERIK 800 mg orally twice daily, steady-state was reached by Day 15. The mean (coefficient of variation [CV]%) steady-state peak plasma concentration (C max ) was 829 (56%) ng/mL and AUC 0-12h was 3340 (49%) ng•h/mL. Tazemetostat exhibited time-dependent pharmacokinetics (PK). The mean accumulation ratio (measured by AUC) was 0.58. Absorption The mean absolute oral bioavailability of tazemetostat is approximately 33%. The median time to reach the peak plasma concentration of tazemetostat is 1 to 2 hours. Effect of Food A high-fat, high-calorie (approximately 800 to 1000 calories) meal does not have a significant effect on tazemetostat exposure. Distribution The mean (CV%) apparent volume of distribution at steady-state (V ss /F) is 1230 L (46%). Tazemetostat is 88% bound to human plasma proteins in vitro. The blood-to-plasma ratio is 0.73. Elimination At steady-state, the estimated mean (CV%) terminal elimination half-life of tazemetostat is 3.1 hours (14%) and the apparent total clearance (CL ss /F) is 274 L/h (49%). Metabolism In vitro, tazemetostat is metabolized by CYP3A to form the inactive major metabolites M5 (EPZ-6930) and M3 (EPZ006931). M5 undergoes further metabolism by CYP3A. Excretion Following a single oral dose of radiolabeled tazemetostat, 94% of the total radioactivity was recovered over 12 days, with 15% excreted into urine and 79% into feces. Specific Populations Age (16 to 91 years), sex, race (White, Black, Asian), body weight (37.3 to 173 kg), mild hepatic impairment (total bilirubin > 1 to 1.5 times ULN or AST > ULN) and renal impairment, including end stage renal disease, have no clinically meaningful effect on the pharmacokinetics of tazemetostat. The effect of moderate to severe hepatic impairment has not been studied. Drug Interaction Studies Clinical Studies Effect of CYP3A Inhibitors on Tazemetostat: Coadministration of fluconazole (a moderate CYP3A inhibitor) with TAZVERIK 400 mg twice daily in patients increased tazemetostat steady-state AUC 0-8h by 3.1-fold and C max by 2.3-fold. Coadministration of itraconazole (a strong CYP3A inhibitor) with TAZVERIK 400 mg twice daily in patients increased tazemetostat steady-state AUC 0-12h by 2.5-fold and C max by 1.9-fold. Effect of CYP3A Inducers on Tazemetostat Coadministration of rifampin (a strong CYP3A inducer) with TAZVERIK 800 mg twice daily in patients decreased tazemetostat steady-state AUC 0-12h by 84% and C max by 84%. Coadministration of tazemetostat with a moderate CYP3A inducer is also predicted to decrease tazemetostat plasma concentrations, which may decrease the efficacy of tazemetostat. Effect of Gastric Acid Reducing Agents on Tazemetostat: Coadministration of omeprazole (a proton pump inhibitor) with TAZVERIK 800 mg twice daily in patients increased tazemetostat steady-state AUC 0-8h by 26% and C max by 25%, which is not expected to have clinically relevant impact. Effect of Tazemetostat on CYP3A Substrate: Coadministration of TAZVERIK 800 mg twice daily with oral midazolam (a sensitive CYP3A substrate) in patients decreased midazolam AUC 0-12h by 40% and C max by 21%. Effect of Tazemetostat on CYP2C8 and CYP2C19 Substrates: Coadministration of TAZVERIK 800 mg twice daily with repaglinide (a sensitive CYP2C8 substrate) and omeprazole (a sensitive CYP2C19 substrate) in patients increased repaglinide AUC 0-8h by 80% and C max by 51%; and had no effect on the exposure of omeprazole. In Vitro Studies Metabolic Enzymes: Tazemetostat does not inhibit CYP1A2, CYP2B6, CYP2C9, and CYP2D6 at clinically relevant concentrations. Drug Transporters: Tazemetostat is a substrate of p-glycoprotein (P-gp). Tazemetostat is not a substrate of breast cancer resistance protein (BCRP); renal transporters organic cation transporter 2 (OCT2), organic anion transporter 3 (OAT3), and multidrug and toxin extrusion transporter 1 (MATE1); or hepatic transporters organic anion transporting polypeptide 1B1 (OATP1B1) and organic anion transporting polypeptide 1B3 (OATP1B3). Tazemetostat is an inhibitor of MATE1 and multidrug and toxin extrusion transporter 2-K (MATE2-K). Tazemetostat does not inhibit P-gp, BCRP, OATP1B1, OATP1B3, organic cation transporter 1 (OCT1), OCT2, organic anion transporter 1 (OAT1), OAT3, or bile salt export pump (BSEP) at clinically relevant concentrations."],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in labeling: Secondary Malignancies [see Warnings and Precautions ( 5.1 )]. The most common (≥20%) adverse reactions in patients with epithelioid sarcoma are pain, fatigue, nausea, decreased appetite, vomiting, and constipation. ( 6.1 ) The most common (≥20%) adverse reactions in patients with follicular lymphoma are fatigue, upper respiratory tract infection, musculoskeletal pain, nausea, and abdominal pain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Epizyme at 855-463-5127 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. Epithelioid Sarcoma The safety of TAZVERIK was evaluated in a cohort (Cohort 5) of Study EZH-202 that enrolled patients with epithelioid sarcoma [see Clinical Studies ( 14.1 )]. Patients received TAZVERIK 800 mg orally twice daily (n=62). Among patients who received TAZVERIK, 44% were exposed for 6 months or longer and 24% were exposed for greater than one year. Serious adverse reactions occurred in 37% of patients who received TAZVERIK. Serious adverse reactions in ≥3% of patients who received TAZVERIK were hemorrhage, pleural effusion, skin infection, dyspnea, pain, and respiratory distress. One patient (2%) permanently discontinued TAZVERIK due to an adverse reaction of altered mood. Dosage interruptions due to an adverse reaction occurred in 34% of patients who received TAZVERIK. The most frequent adverse reactions requiring dosage interruptions in ≥3% were hemorrhage, increased alanine aminotransferase (ALT), and increased aspartate aminotransferase (AST). Dose reduction due to an adverse reaction occurred in one (2%) patient who received TAZVERIK; the dose was reduced in this patient for decreased appetite. The most common adverse reactions (≥20%) were pain, fatigue, nausea, decreased appetite, vomiting, and constipation. Table 4 presents adverse reactions in patients with epithelioid sarcoma in Cohort 5 of Study EZH-202. Table 4. Adverse Reactions (≥10%) in Patients with Epithelioid Sarcoma Who Received TAZVERIK in Cohort 5 of Study EZH-202 Adverse Reaction TAZVERIK N=62 All Grades (%) Grade 3 or 4 (%) a Includes tumor pain, pain in extremity, non-cardiac chest pain, flank pain, back pain, arthralgia, bone pain, cancer pain, musculoskeletal pain, myalgia, neck pain b Includes fatigue and asthenia c Includes abdominal pain, gastrointestinal pain, abdominal pain lower d Includes dyspnea and dyspnea exertional e Includes wound hemorrhage, rectal hemorrhage, pulmonary hemorrhage, hemorrhage intracranial, cerebral hemorrhage, hemoptysis General Pain a 52 7 Fatigue b 47 1.6 Gastrointestinal Nausea 36 0 Vomiting 24 0 Constipation 21 0 Diarrhea 16 0 Abdominal pain c 13 1.6 Metabolism and nutrition Decreased appetite 26 4.8 Respiratory, thoracic and mediastinal Cough 18 0 Dyspnea d 16 4.8 Vascular Hemorrhage e 18 4.8 Nervous system Headache 18 0 Investigations Weight decreased 16 7 Table 5 summarizes select laboratory abnormalities in patients with epithelioid sarcoma in Cohort 5 of Study EZH-202. Table 5. Select Laboratory Abnormalities (≥ 10%) Worsening from Baseline in Patients with Epithelioid Sarcoma Who Received TAZVERIK in Cohort 5 of Study EZH-202 *The denominator used to calculate the rate varied from 39 to 61 based on the number of patients with a baseline value and at least one post-treatment value. Laboratory Abnormality TAZVERIK* All Grades (%) Grade 3 or 4 (%) Hematology Decreased hemoglobin 49 15 Decreased lymphocytes 36 13 Decreased white blood cell count 19 0 Chemistry Increased triglycerides 36 3.3 Increased glucose 33 1.6 Decreased sodium 30 1.7 Decreased phosphate 28 1.7 Decreased albumin 23 0 Increased alkaline phosphatase 23 1.7 Decreased potassium 20 1.7 Increased aspartate aminotransferase 18 3.5 Decreased calcium 16 0 Decreased glucose 16 0 Increased partial thromboplastin time 15 5 Increased alanine aminotransferase 14 3.4 Increased creatinine 12 0 Increased potassium 12 0 Relapsed or Refractory Follicular Lymphoma The safety of TAZVERIK was evaluated in two cohorts (Cohorts 4 and 5) of Study E7438-G000-101 that enrolled patients with relapsed or refractory follicular lymphoma [see Clinical Studies ( 14.2 )]. Patients received TAZVERIK 800 mg orally twice daily (n=99). Among patients who received TAZVERIK, 68% were exposed for 6 months or longer, 39% were exposed for 12 months or longer, and 21% were exposed for 18 months or longer. The median age was 62 years (range 36 to 87 years), 54% were male, and 95% had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. The median number of prior therapies was 3 (range 1 to 11). Patients were required to have a creatinine clearance ≥40 mL/min per the Cockcroft and Gault formula. Serious adverse reactions occurred in 30% of patients who received TAZVERIK. Serious adverse reactions in ≥2% of patients who received TAZVERIK were general physical health deterioration, abdominal pain, pneumonia, sepsis, and anemia. Permanent discontinuation due to an adverse reaction occurred in 8% of patients who received TAZVERIK. Adverse reaction resulting in permanent discontinuation in ≥2% of patients was second primary malignancy. Dosage interruptions due to an adverse reaction occurred in 28% of patients who received TAZVERIK. Adverse reactions requiring dosage interruptions in ≥3% of patients were thrombocytopenia and fatigue. Dose reduction due to an adverse reaction occurred in 9% of patients who received TAZVERIK. The most common adverse reactions (≥20%) were fatigue, upper respiratory tract infection, musculoskeletal pain, nausea, and abdominal pain. Table 6 presents adverse reactions in patients with relapsed or refractory follicular lymphoma in Cohorts 4 and 5 of Study E7438-G000-101. Table 6. Adverse Reactions (≥10%) in Patients with Relapsed or Refractory Follicular Lymphoma Who Received TAZVERIK in Cohorts 4 and 5 of Study E7438-G000-101 Adverse Reaction TAZVERIK N=99 All Grades (%) Grade 3 or 4 (%) a Includes fatigue and asthenia b Includes laryngitis, nasopharyngitis, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, viral upper respiratory tract infection c Includes bronchitis, lower respiratory tract infection, tracheobronchitis d Includes cystitis, urinary tract infection, urinary tract infection staphylococcal e Includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper f Includes back pain, limb discomfort, musculoskeletal chest pain, musculoskeletal discomfort, musculoskeletal pain, myalgia, neck pain, non-cardiac chest pain, pain in extremity, pain in jaw, spinal pain g Includes erythema, rash, rash erythematous, rash generalized, rash maculo-papular, rash pruritic, rash pustular, skin exfoliation h Includes cough and productive cough i Includes headache, migraine, sinus headache General Fatigue a 36 5 Pyrexia 10 0 Infections Upper respiratory tract infection b 30 0 Lower respiratory tract infection c 17 0 Urinary tract infection d 11 2 Gastrointestinal Nausea 24 1 Abdominal pain e 20 3 Diarrhea 18 0 Vomiting 12 1 Musculoskeletal and connective tissue Musculoskeletal pain f 22 1 Skin and subcutaneous tissue Alopecia 17 0 Rash g 15 0 Respiratory and mediastinal system Cough h 17 0 Nervous system Headache i 13 0 Clinically relevant adverse reactions occurring in <10% of patients who received TAZVERIK included: Infection: sepsis (2%), pneumonia (2%), and herpes zoster (2%) Table 7 summarizes select laboratory abnormalities in patients with follicular lymphoma in Cohorts 4 and 5 of Study E7438-G000-101. Table 7. Select Laboratory Abnormalities (≥10%) Worsening from Baseline in Patients with Relapsed or Refractory Follicular Lymphoma Who Received TAZVERIK in Cohorts 4 and 5 of Study E7438-G000-101 Laboratory Abnormality TAZVERIK* All Grades (%) Grade 3 or 4 (%) *The denominator used to calculate the rate varied from 88 to 96 based on the number of patients with a baseline value and at least one post-treatment value. Hematology Decreased lymphocytes 57 18 Decreased hemoglobin 50 8 Decreased platelets 50 7 Decreased white blood cells 41 9 Decreased neutrophils 20 7 Chemistry Increased glucose 53 10 Increased aspartate aminotransferase 24 0 Increased alanine aminotransferase 21 2.3 Increased alkaline phosphatase 18 1.0 Increased creatinine 17 0"],"contraindications":["4 CONTRAINDICATIONS None. None. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS Strong or Moderate Cytochrome P450 (CYP)3A Inhibitors : Avoid coadministration of strong or moderate CYP3A inhibitors with TAZVERIK. Reduce the dose of TAZVERIK if coadministration of strong or moderate CYP3A inhibitors cannot be avoided. ( 2.3 , 7.1 ) Strong or Moderate CYP3A Inducers : Avoid coadministration with TAZVERIK. ( 7.1 ) 7.1 Effect of Other Drugs on TAZVERIK Strong or Moderate CYP3A Inhibitors Coadministration of TAZVERIK with a strong or moderate CYP3A inhibitor increases tazemetostat plasma concentrations [see Clinical Pharmacology ( 12.3 )], which may increase the frequency or severity of adverse reactions. Avoid coadministration of strong or moderate CYP3A inhibitors with TAZVERIK. If coadministration of strong or moderate CYP3A inhibitors cannot be avoided, reduce TAZVERIK dose [see Dosage and Administration ( 2.4 )]. Strong or Moderate CYP3A Inducers Coadministration of TAZVERIK with a strong CYP3A inducer decreases tazemetostat plasma concentrations [see Clinical Pharmacology ( 12.3 )] , and coadministration of TAZVERIK with a moderate CYP3A inducer may also decrease tazemetostat plasma concentrations. The decrease in tazemetostat plasma concentration may decrease the efficacy of TAZVERIK. Avoid coadministration of moderate or strong CYP3A inducers with TAZVERIK. 7.2 Effect of TAZVERIK on Other Drugs CYP3A Substrates Coadministration of TAZVERIK with CYP3A substrates, including hormonal contraceptives, can result in decreased concentrations and reduced efficacy of CYP3A substrates [see Use in Specific Populations ( 8.3 ), Clinical Pharmacology ( 12.3 )] ."],"spl_medguide_table":["
This Medication Guide has been approved by the U.S. Food and Drug Administration.Issued: November/2023
MEDICATION GUIDE TAZVERIK® (taz vayr′ ik) (tazemetostat) tablets
What is the most important information I should know about TAZVERIK? TAZVERIK can cause serious side effects, including:Risk of new cancers. An increase in new (second) cancers has happened in people who were treated with TAZVERIK. Talk with your healthcare provider about your risk of developing new cancers. Your healthcare provider will monitor you for new cancers after your treatment with TAZVERIK. Tell your healthcare provider if you are more tired than usual, or have easy bruising, fever, bone pain, or paleness.See "What are the possible side effects of TAZVERIK" for more information about side effects.
What is TAZVERIK? TAZVERIK is a prescription medicine used to treat: adults and children aged 16 years and older with epithelioid sarcoma that has spread or grown and cannot be removed by surgery.adults with follicular lymphoma when the disease has come back or did not respond to treatment, whose tumors have an abnormal EZH2 gene, and who have been treated with at least two prior medicines. Your healthcare provider will perform a test to make sure TAZVERIK is right for you.adults with follicular lymphoma when the disease has come back or did not respond to treatment, who have no other satisfactory treatment options. It is not known if TAZVERIK is safe and effective in children less than 16 years of age.
Before taking TAZVERIK tell your healthcare provider about all of your medical conditions, including if you: are pregnant or plan to become pregnant. TAZVERIK can harm your unborn baby. Your healthcare provider will give you a pregnancy test before you start treatment with TAZVERIK. Tell your healthcare provider right away if you become pregnant or think you may be pregnant.Females who are able to become pregnant should use effective non-hormonal birth control (such as condoms) during treatment and for 6 months after the final dose of TAZVERIK. Birth control pills (oral contraceptives) and other hormonal forms of birth control may not be effective if used during treatment with TAZVERIK. Talk to your healthcare provider about birth control options that are right for you.Males with female partners who are able to become pregnant should use effective birth control during treatment and for 3 months after the final dose of TAZVERIK.are breastfeeding or plan to breastfeed. It is not known if TAZVERIK passes into your breast milk. Do not breastfeed during treatment and for 1 week after the final dose of TAZVERIK.Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. TAZVERIK may affect the way other medicines work and other medicines may affect how TAZVERIK works.
How should I take TAZVERIK? Take TAZVERIK exactly as your healthcare provider tells you.Take TAZVERIK 2 times each day.Take TAZVERIK with or without food.Swallow TAZVERIK tablets whole. Do not cut, crush, or chew tablets.If you miss a dose or vomit after taking your dose, just skip that dose and take the next dose at your regular time.Your healthcare provider may change your dose, temporarily stop, or completely stop treatment with TAZVERIK if you get certain side effects.
What should I avoid while taking TAZVERIK? Avoid eating grapefruit or drinking grapefruit juice during treatment with TAZVERIK.Avoid taking St. John's wort during treatment with TAZVERIK.
What are the possible side effects of TAZVERIK? TAZVERIK can cause serious side effects. See "What is the most important information I should know about TAZVERIK?" The most common side effects of TAZVERIK in people with epithelioid sarcoma include:
painnauseavomiting
tirednessdecreased appetiteconstipation
The most common side effects of TAZVERIK in people with follicular lymphoma include:
tirednessbone and muscle pain
cold-like symptoms (upper respiratory infection)nausea
stomach (abdominal) pain
These are not all the possible side effects of TAZVERIK. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store TAZVERIK? Do not store TAZVERIK tablets above 86°F (30°C). Keep TAZVERIK and all medicines out of the reach of children.
General information about the safe and effective use of TAZVERIK. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use TAZVERIK for a condition for which it was not prescribed. Do not give TAZVERIK to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about TAZVERIK that is written for health professionals.
What are the ingredients in TAZVERIK? Active Ingredient: tazemetostat. Inactive Ingredients: Tablet core: hydroxypropyl cellulose, lactose monohydrate, low-substituted hydroxypropyl cellulose, magnesium stearate, and sodium starch glycolate. Film-coating: hypromellose, polyethylene glycol, red iron oxide, talc, and titanium dioxide. Manufactured for: Epizyme, Inc. An Ipsen Company One Main St. Cambridge, MA 02142 For more information, contact Epizyme at 855-463-5127.
"],"mechanism_of_action":["12.1 Mechanism of Action Tazemetostat is an inhibitor of the methyltransferase, EZH2, and some EZH2 gain-of-function mutations including Y646X, A682G, and A692V. Tazemetostat also inhibited EZH1 with a half-maximal inhibitory concentration (IC 50 ) of 392 nM, approximately 36 times higher than the IC 50 for inhibition of EZH2. The most well-characterized function of EZH2 is as the catalytic subunit of the polycomb repressive complex 2 (PRC2), catalyzing mono-, di-, and trimethylation of lysine 27 of histone H3. Trimethylation of histone H3 leads to transcriptional repression. SWItch/Sucrose Non-Fermentable (SWI/SNF) complexes can antagonize PRC2 function in the regulation of the expression of certain genes of patients with epithelioid sarcoma. Preclinical in vitro and in vivo models with the loss or dysfunction of certain SWI/SNF complex members (e.g., integrase interactor 1 [INI1/SNF5/SMARCB1/BAF47], SMARCA4, and SMARCA2) can lead to aberrant EZH2 activity or expression and a resulting oncogenic dependence on EZH2. Tazemetostat suppressed proliferation of B-cell lymphoma cell lines in vitro and demonstrated antitumor activity in a mouse xenograft model of B-cell lymphoma with or without EZH2 gain-of-function mutations. Tazemetostat demonstrated greater effects on the inhibition of proliferation of lymphoma cell lines with mutant EZH2."],"recent_major_changes":["Dosage and Administration, Modifications for Drug Interactions ( 2.4 ) 08/2024 Warnings and Precautions, Secondary Malignancies ( 5.1 ) 11/2023"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Tazemetostat is an inhibitor of the methyltransferase, EZH2, and some EZH2 gain-of-function mutations including Y646X, A682G, and A692V. Tazemetostat also inhibited EZH1 with a half-maximal inhibitory concentration (IC 50 ) of 392 nM, approximately 36 times higher than the IC 50 for inhibition of EZH2. The most well-characterized function of EZH2 is as the catalytic subunit of the polycomb repressive complex 2 (PRC2), catalyzing mono-, di-, and trimethylation of lysine 27 of histone H3. Trimethylation of histone H3 leads to transcriptional repression. SWItch/Sucrose Non-Fermentable (SWI/SNF) complexes can antagonize PRC2 function in the regulation of the expression of certain genes of patients with epithelioid sarcoma. Preclinical in vitro and in vivo models with the loss or dysfunction of certain SWI/SNF complex members (e.g., integrase interactor 1 [INI1/SNF5/SMARCB1/BAF47], SMARCA4, and SMARCA2) can lead to aberrant EZH2 activity or expression and a resulting oncogenic dependence on EZH2. Tazemetostat suppressed proliferation of B-cell lymphoma cell lines in vitro and demonstrated antitumor activity in a mouse xenograft model of B-cell lymphoma with or without EZH2 gain-of-function mutations. Tazemetostat demonstrated greater effects on the inhibition of proliferation of lymphoma cell lines with mutant EZH2. 12.2 Pharmacodynamics Tazemetostat exposure-response relationships and the time course of pharmacodynamic responses are unknown. Cardiac Electrophysiology The effect of orally administered TAZVERIK, at doses ranging from 100 mg to 1600 mg twice daily (0.125 to 2 times the approved recommended dosage) for 15 days, on the heart-rate corrected QT (QTc) interval was evaluated in a dose-finding study in 38 patients with advanced malignancies. Tazemetostat and its metabolite EPZ-6930 did not cause a large mean increase (i.e. >20 ms) on the QTc interval at the 800 mg twice daily dose. The largest mean increase (upper bound of 90% confidence interval) in QTc were 6.1 ms (8.5 ms) and 9.3 ms (12.5 ms) at a dose of 800 mg twice daily and 1600 mg twice daily, respectively. 12.3 Pharmacokinetics The systemic exposure of tazemetostat is approximately dose proportional over the dose range of 200 mg to 1600 mg twice daily of TAZVERIK (0.25 to 2 times the approved recommended dosage). Following TAZVERIK 800 mg orally twice daily, steady-state was reached by Day 15. The mean (coefficient of variation [CV]%) steady-state peak plasma concentration (C max ) was 829 (56%) ng/mL and AUC 0-12h was 3340 (49%) ng•h/mL. Tazemetostat exhibited time-dependent pharmacokinetics (PK). The mean accumulation ratio (measured by AUC) was 0.58. Absorption The mean absolute oral bioavailability of tazemetostat is approximately 33%. The median time to reach the peak plasma concentration of tazemetostat is 1 to 2 hours. Effect of Food A high-fat, high-calorie (approximately 800 to 1000 calories) meal does not have a significant effect on tazemetostat exposure. Distribution The mean (CV%) apparent volume of distribution at steady-state (V ss /F) is 1230 L (46%). Tazemetostat is 88% bound to human plasma proteins in vitro. The blood-to-plasma ratio is 0.73. Elimination At steady-state, the estimated mean (CV%) terminal elimination half-life of tazemetostat is 3.1 hours (14%) and the apparent total clearance (CL ss /F) is 274 L/h (49%). Metabolism In vitro, tazemetostat is metabolized by CYP3A to form the inactive major metabolites M5 (EPZ-6930) and M3 (EPZ006931). M5 undergoes further metabolism by CYP3A. Excretion Following a single oral dose of radiolabeled tazemetostat, 94% of the total radioactivity was recovered over 12 days, with 15% excreted into urine and 79% into feces. Specific Populations Age (16 to 91 years), sex, race (White, Black, Asian), body weight (37.3 to 173 kg), mild hepatic impairment (total bilirubin > 1 to 1.5 times ULN or AST > ULN) and renal impairment, including end stage renal disease, have no clinically meaningful effect on the pharmacokinetics of tazemetostat. The effect of moderate to severe hepatic impairment has not been studied. Drug Interaction Studies Clinical Studies Effect of CYP3A Inhibitors on Tazemetostat: Coadministration of fluconazole (a moderate CYP3A inhibitor) with TAZVERIK 400 mg twice daily in patients increased tazemetostat steady-state AUC 0-8h by 3.1-fold and C max by 2.3-fold. Coadministration of itraconazole (a strong CYP3A inhibitor) with TAZVERIK 400 mg twice daily in patients increased tazemetostat steady-state AUC 0-12h by 2.5-fold and C max by 1.9-fold. Effect of CYP3A Inducers on Tazemetostat Coadministration of rifampin (a strong CYP3A inducer) with TAZVERIK 800 mg twice daily in patients decreased tazemetostat steady-state AUC 0-12h by 84% and C max by 84%. Coadministration of tazemetostat with a moderate CYP3A inducer is also predicted to decrease tazemetostat plasma concentrations, which may decrease the efficacy of tazemetostat. Effect of Gastric Acid Reducing Agents on Tazemetostat: Coadministration of omeprazole (a proton pump inhibitor) with TAZVERIK 800 mg twice daily in patients increased tazemetostat steady-state AUC 0-8h by 26% and C max by 25%, which is not expected to have clinically relevant impact. Effect of Tazemetostat on CYP3A Substrate: Coadministration of TAZVERIK 800 mg twice daily with oral midazolam (a sensitive CYP3A substrate) in patients decreased midazolam AUC 0-12h by 40% and C max by 21%. Effect of Tazemetostat on CYP2C8 and CYP2C19 Substrates: Coadministration of TAZVERIK 800 mg twice daily with repaglinide (a sensitive CYP2C8 substrate) and omeprazole (a sensitive CYP2C19 substrate) in patients increased repaglinide AUC 0-8h by 80% and C max by 51%; and had no effect on the exposure of omeprazole. In Vitro Studies Metabolic Enzymes: Tazemetostat does not inhibit CYP1A2, CYP2B6, CYP2C9, and CYP2D6 at clinically relevant concentrations. Drug Transporters: Tazemetostat is a substrate of p-glycoprotein (P-gp). Tazemetostat is not a substrate of breast cancer resistance protein (BCRP); renal transporters organic cation transporter 2 (OCT2), organic anion transporter 3 (OAT3), and multidrug and toxin extrusion transporter 1 (MATE1); or hepatic transporters organic anion transporting polypeptide 1B1 (OATP1B1) and organic anion transporting polypeptide 1B3 (OATP1B3). Tazemetostat is an inhibitor of MATE1 and multidrug and toxin extrusion transporter 2-K (MATE2-K). Tazemetostat does not inhibit P-gp, BCRP, OATP1B1, OATP1B3, organic cation transporter 1 (OCT1), OCT2, organic anion transporter 1 (OAT1), OAT3, or bile salt export pump (BSEP) at clinically relevant concentrations."],"indications_and_usage":["1 INDICATIONS AND USAGE TAZVERIK is a methyltransferase inhibitor indicated for the treatment of: Adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. ( 1.1 ) Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. ( 1.2 ) Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. ( 1.2 ) These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 1.1 Epithelioid Sarcoma TAZVERIK is indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies ( 14.1 )]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 1.2 Relapsed or Refractory Follicular Lymphoma TAZVERIK is indicated for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. TAZVERIK is indicated for the treatment of adult patients with R/R FL who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies ( 14.2 )]. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s)."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Secondary Malignancies : TAZVERIK increases the risk of developing secondary malignancies, including T-cell lymphoblastic lymphoma, myelodysplastic syndrome, acute myeloid leukemia, and B-cell acute lymphoblastic leukemia. Monitor patients long-term for the development of secondary malignancies. ( 5.1 ) Embryo-Fetal Toxicity : Can cause fetal harm. Advise patients of potential risk to a fetus and to use effective non-hormonal contraception. ( 5.2 ) 5.1 Secondary Malignancies The risk of developing secondary malignancies is increased following treatment with TAZVERIK. Across clinical trials of 758 adults who received TAZVERIK 800 mg twice daily as monotherapy, myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), or B-cell acute lymphoblastic leukemia (B-ALL) occurred in 1.7% of patients. One pediatric patient developed T-cell lymphoblastic lymphoma (T-LBL). Monitor patients long-term for the development of secondary malignancies. 5.2 Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, TAZVERIK can cause fetal harm when administered to pregnant women. There are no available data on TAZVERIK use in pregnant women to inform the drug-associated risk. Administration of tazemetostat to pregnant rats and rabbits during organogenesis resulted in dose-dependent increases in skeletal developmental abnormalities in both species beginning at maternal exposures approximately 1.5 times the adult human exposure (area under the plasma concentration time curve [AUC 0-45h ]) at the 800 mg twice daily dose. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TAZVERIK and for 6 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with TAZVERIK and for 3 months after the final dose [see Use in Specific Populations ( 8.1 , 8.3 )] ."],"clinical_studies_table":["
Table 8. Efficacy Results for Patients with Epithelioid Sarcoma Enrolled in Cohort 5 of Study EZH-202
CI = Confidence Interval
*Time to response ranged from 1.4 to 18.4 months.
Efficacy EndpointsTAZVERIK N=62
Overall Response Rate (95% CI)*15% (7%, 26%)
Complete Response1.6%
Partial Response13%
Duration of Response
% with duration ≥ 6 months67%
Range in months3.7, 24.5+
","
Table 9. Efficacy Results for Patients with Relapsed or Refractory Follicular Lymphoma Enrolled into Cohorts 4 and 5 of Study E7438-G000-101
CI = Confidence Interval; NE = Not Estimable.
*Median time to response for patients with EZH2 MT follicular lymphoma was 3.7 months (range 1.6 to 10.9) and for patients with EZH2 WT follicular lymphoma was 3.9 months (range 1.6 to 16.3).
Efficacy EndpointsTAZVERIK N=95
EZH2 Mutant Follicular Lymphoma N=42EZH2 Wild-Type Follicular Lymphoma N=53
Overall Response Rate (95% CI)*69% (53%, 82%)34% (22%, 48%)
Complete Response12%4%
Partial Response57%30%
Duration of Response
Median (95% CI) in months10.9 (7.2, NE)13.0 (5.6, NE)
Range in months0.0+, 22.1+1, 22.5+
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Dedicated carcinogenicity studies were not conducted with tazemetostat, but T-LBL, MDS, AML, and B-ALL have been reported clinically and T-LBL occurred in juvenile and adult rats after ~9 or more weeks of tazemetostat administration during 13-week toxicity studies. Based on nonclinical studies in rats, the risk of T-LBL appears to be greater with longer duration dosing. Tazemetostat did not cause genetic damage in a standard battery of studies including a screening and pivotal bacterial reverse mutation (Ames) assay, an in vitro micronucleus assessment in human peripheral blood lymphocytes, and an in vivo micronucleus assessment in rats after oral administration. Fertility and early embryonic development studies have not been conducted with tazemetostat; however, assessments of male and female reproductive organs were included in 4- and 13-week repeat-dose toxicity studies in rats and cynomolgus monkeys. Oral daily administration of tazemetostat did not result in any notable effects in the adult male and female reproductive organs [see Use in Specific Populations ( 8.3 )] ."],"adverse_reactions_table":["
Table 4. Adverse Reactions (≥10%) in Patients with Epithelioid Sarcoma Who Received TAZVERIK in Cohort 5 of Study EZH-202
Adverse ReactionTAZVERIK N=62
All Grades (%)Grade 3 or 4 (%)
a Includes tumor pain, pain in extremity, non-cardiac chest pain, flank pain, back pain, arthralgia, bone pain, cancer pain, musculoskeletal pain, myalgia, neck pain
b Includes fatigue and asthenia
c Includes abdominal pain, gastrointestinal pain, abdominal pain lower
d Includes dyspnea and dyspnea exertional
e Includes wound hemorrhage, rectal hemorrhage, pulmonary hemorrhage, hemorrhage intracranial, cerebral hemorrhage, hemoptysis
General
Paina527
Fatigueb471.6
Gastrointestinal
Nausea360
Vomiting240
Constipation210
Diarrhea160
Abdominal painc131.6
Metabolism and nutrition
Decreased appetite264.8
Respiratory, thoracic and mediastinal
Cough180
Dyspnead164.8
Vascular
Hemorrhagee184.8
Nervous system
Headache180
Investigations
Weight decreased167
","
Table 5. Select Laboratory Abnormalities (≥ 10%) Worsening from Baseline in Patients with Epithelioid Sarcoma Who Received TAZVERIK in Cohort 5 of Study EZH-202
*The denominator used to calculate the rate varied from 39 to 61 based on the number of patients with a baseline value and at least one post-treatment value.
Laboratory AbnormalityTAZVERIK*
All Grades (%)Grade 3 or 4 (%)
Hematology
Decreased hemoglobin4915
Decreased lymphocytes3613
Decreased white blood cell count190
Chemistry
Increased triglycerides363.3
Increased glucose331.6
Decreased sodium301.7
Decreased phosphate281.7
Decreased albumin230
Increased alkaline phosphatase231.7
Decreased potassium201.7
Increased aspartate aminotransferase183.5
Decreased calcium160
Decreased glucose160
Increased partial thromboplastin time155
Increased alanine aminotransferase143.4
Increased creatinine120
Increased potassium120
","
Table 6. Adverse Reactions (≥10%) in Patients with Relapsed or Refractory Follicular Lymphoma Who Received TAZVERIK in Cohorts 4 and 5 of Study E7438-G000-101
Adverse ReactionTAZVERIK N=99
All Grades (%)Grade 3 or 4 (%)
a Includes fatigue and asthenia
b Includes laryngitis, nasopharyngitis, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, viral upper respiratory tract infection
c Includes bronchitis, lower respiratory tract infection, tracheobronchitis
d Includes cystitis, urinary tract infection, urinary tract infection staphylococcal
e Includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper
f Includes back pain, limb discomfort, musculoskeletal chest pain, musculoskeletal discomfort, musculoskeletal pain, myalgia, neck pain, non-cardiac chest pain, pain in extremity, pain in jaw, spinal pain
g Includes erythema, rash, rash erythematous, rash generalized, rash maculo-papular, rash pruritic, rash pustular, skin exfoliation
h Includes cough and productive cough
i Includes headache, migraine, sinus headache
General
Fatiguea365
Pyrexia100
Infections
Upper respiratory tract infectionb300
Lower respiratory tract infectionc170
Urinary tract infectiond112
Gastrointestinal
Nausea241
Abdominal paine203
Diarrhea180
Vomiting121
Musculoskeletal and connective tissue
Musculoskeletal painf221
Skin and subcutaneous tissue
Alopecia170
Rashg150
Respiratory and mediastinal system
Coughh170
Nervous system
Headachei130
","
Table 7. Select Laboratory Abnormalities (≥10%) Worsening from Baseline in Patients with Relapsed or Refractory Follicular Lymphoma Who Received TAZVERIK in Cohorts 4 and 5 of Study E7438-G000-101
Laboratory AbnormalityTAZVERIK*
All Grades (%)Grade 3 or 4 (%)
*The denominator used to calculate the rate varied from 88 to 96 based on the number of patients with a baseline value and at least one post-treatment value.
Hematology
Decreased lymphocytes5718
Decreased hemoglobin508
Decreased platelets507
Decreased white blood cells419
Decreased neutrophils207
Chemistry
Increased glucose5310
Increased aspartate aminotransferase240
Increased alanine aminotransferase212.3
Increased alkaline phosphatase181.0
Increased creatinine170
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling ( Medication Guide ). Secondary Malignancies Advise patients of the increased risk of secondary hematologic malignancies. Advise patients to inform their healthcare provider if they experience fatigue, easy bruising, fever, bone pain, or paleness [see Warnings and Precautions ( 5.1 )] . Embryo-Fetal Toxicity Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy [see Use in Specific Populations ( 8.1 )] . Advise females of reproductive potential to use effective non-hormonal contraception during treatment with TAZVERIK and for 6 months after the final dose [see Use in Specific Populations ( 8.3 )] . Advise males with female partners of reproductive potential to use effective contraception during treatment with TAZVERIK and for 3 months after the final dose [see Use in Specific Populations ( 8.3 ), Nonclinical Toxicology ( 13.1 )]. Lactation Advise women not to breastfeed during treatment with TAZVERIK and for 1 week after the final dose [see Use in Special Populations ( 8.2 )]. Drug Interactions Advise patients and caregivers to inform their healthcare provider of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, and herbal products. Inform patients to avoid St. John's wort, grapefruit, and grapefruit juice while taking TAZVERIK [see Drug Interactions ( 7.1 )] . Manufactured for: Epizyme, Inc. An Ipsen Company One Main St. Cambridge, MA 02142 ©2023, 2024 Epizyme, Inc."],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Recommended dosage is 800 mg taken orally twice daily with or without food. ( 2.2 ) 2.1 Patient Selection Select patients with R/R FL for treatment with TAZVERIK based on the presence of EZH2 mutation of codons Y646, A682, or A692 in tumor specimens [see Clinical Studies ( 14.2 )] . Information on FDA-approved tests for the detection of EZH2 mutation in relapsed or refractory follicular lymphoma is available at: http://www.fda.gov/CompanionDiagnostics. 2.2 Recommended Dosage The recommended dosage of TAZVERIK is 800 mg orally twice daily with or without food until disease progression or unacceptable toxicity. Swallow tablets whole. Do not cut, crush, or chew tablets. Do not take an additional dose if a dose is missed or vomiting occurs after TAZVERIK, but continue with the next scheduled dose. 2.3 Dosage Modifications for Adverse Reactions Table 1 summarizes the recommended dose reductions, and Table 2 summarizes the recommended dosage modifications of TAZVERIK for adverse reactions. Table 1. Recommended Dose Reductions of TAZVERIK for Adverse Reactions *Permanently discontinue TAZVERIK in patients who are unable to tolerate 400 mg orally twice daily. Dose Reduction Dosage First 600 mg orally twice daily Second 400 mg orally twice daily* Table 2. Recommended Dosage Modifications of TAZVERIK for Adverse Reactions Adverse Reaction Severity Dosage Modification Neutropenia [see Adverse Reactions ( 6.1 )] Neutrophil count less than 1 × 10 9 /L Withhold until neutrophil count is greater than or equal to 1 × 10 9 /L or baseline. For first occurrence, resume at same dose. For second and third occurrence, resume at reduced dose. Permanently discontinue after fourth occurrence. Thrombocytopenia [see Adverse Reactions ( 6.1 )] Platelet count less than 50 × 10 9 /L Withhold until platelet count is greater than or equal to 75 × 10 9 /L or baseline. For first and second occurrence, resume at reduced dose. Permanently discontinue after third occurrence. Anemia [see Adverse Reactions ( 6.1 )] Hemoglobin less than 8 g/dL Withhold until improvement to at least Grade 1 or baseline, then resume at same or reduced dose. Other adverse reactions [see Adverse Reactions ( 6.1 )] Grade 3 Withhold until improvement to at least Grade 1 or baseline. For first and second occurrence, resume at reduced dose. Permanently discontinue after third occurrence. Grade 4 Withhold until improvement to at least Grade 1 or baseline. For first occurrence, resume at reduced dose. Permanently discontinue after second occurrence. 2.4 Dosage Modifications for Drug Interactions Strong or Moderate CYP3A Inhibitors Avoid coadministration of TAZVERIK with strong or moderate CYP3A inhibitors. If coadministration with a strong or moderate CYP3A inhibitor cannot be avoided, reduce the TAZVERIK dose as shown in Table 3 below. After discontinuation of the strong or moderate CYP3A inhibitor for 3 elimination half-lives, resume the TAZVERIK dose that was taken prior to initiating the inhibitor [see Drug Interactions ( 7.1 ), Clinical Pharmacology ( 12.3 )] . Table 3. Recommended Dose Reductions of TAZVERIK for Strong or Moderate CYP3A Inhibitors Current Dosage Adjusted Dosage 800 mg orally twice daily 400 mg orally twice daily 600 mg orally twice daily 400 mg for first dose and 200 mg for second dose 400 mg orally twice daily 200 mg orally twice daily"],"spl_product_data_elements":["TAZVERIK tazemetostat tazemetostat hydrobromide tazemetostat Lactose monohydrate Low-substituted hydroxypropyl cellulose, unspecified Hydroxypropyl cellulose, unspecified Sodium starch glycolate Type A potato Magnesium stearate Hypromellose, unspecified Talc Polyethylene glycol 8000 Titanium dioxide Ferric oxide red RED ROUND EZM;200"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Tablets: 200 mg film-coated, red, round, biconvex shape and debossed with \"EZM 200\" on one side and plain on the other. Tablets: 200 mg ( 3 )"],"recent_major_changes_table":["
Dosage and Administration, Modifications for Drug Interactions (2.4) 08/2024
Warnings and Precautions, Secondary Malignancies (5.1)11/2023
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation : Advise not to breastfeed. ( 8.2 ) 8.1 Pregnancy Risk Summary Based on findings from animal studies and its mechanism of action [see Clinical Pharmacology ( 12.1 )] , TAZVERIK can cause fetal harm when administered to pregnant women. There are no available data on TAZVERIK use in pregnant women to inform the drug-associated risk. Administration of tazemetostat to pregnant rats and rabbits during organogenesis resulted in dose-dependent increases in skeletal developmental abnormalities in both species beginning at maternal exposures approximately 1.5 times the adult human exposure [AUC 0-45h ] at the 800 mg twice daily dose (see Data ) . Advise pregnant women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In pregnant rats, once daily oral administration of tazemetostat during the period of organogenesis from gestation day (GD) 7 through 17 resulted in no maternal adverse effects at doses up to 100 mg/kg/day (approximately 6 times the adult human exposure at 800 mg twice daily). Skeletal malformations and variations occurred in fetuses at doses of ≥50 mg/kg (approximately 2 times the adult human exposure at the 800 mg twice daily dose). At 200 mg/kg (approximately 14 times the adult human exposure at the 800 mg twice daily dose), major findings included increased post implantation loss, missing digits, fused vertebrae, domed heads and fused bones of the skull, and reduced fetal body weights. In pregnant rabbits, no adverse maternal effects were observed after once daily oral administration of 400 mg/kg/day tazemetostat (approximately 7 times the adult human exposure at the 800 mg twice daily dose) from GD 7 through 19. Skeletal variations were present at doses ≥100 mg/kg/day (approximately 1.5 times the adult human exposure at the 800 mg twice daily dose), with skeletal malformations at ≥200 mg/kg/day (approximately 5.6 times the adult human exposure at the 800 mg twice daily dose). At 400 mg/kg (approximately 7 times the adult human exposure at the 800 mg twice daily dose), major findings included increased post implantation loss and cleft palate and snout. 8.2 Lactation Risk Summary There are no animal or human data on the presence of tazemetostat in human milk or on its effects on the breastfed child or milk production. Because of the potential risk for serious adverse reactions from TAZVERIK in the breastfed child, advise women not to breastfeed during treatment with TAZVERIK and for one week after the final dose. 8.3 Females and Males of Reproductive Potential Pregnancy Testing Verify the pregnancy status of females of reproductive potential prior to initiating TAZVERIK [see Use in Specific Populations ( 8.1 ) ] . Risk Summary TAZVERIK can cause fetal harm when administered to pregnant women [see Use in Specific Populations ( 8.1 )] . Contraception Females Advise females of reproductive potential to use effective non-hormonal contraception during treatment with TAZVERIK and for 6 months after the final dose. TAZVERIK can render some hormonal contraceptives ineffective [see Drug Interactions ( 7.2 )] . Males Advise males with female partners of reproductive potential to use effective contraception during treatment with TAZVERIK and for at least 3 months after the final dose. 8.4 Pediatric Use The safety and effectiveness of TAZVERIK have been established in pediatric patients aged 16 years and older (adolescents) with metastatic or locally advanced epithelioid sarcoma. Use of TAZVERIK for this indication is supported by evidence from adequate and well-controlled studies in adults (including 3 adolescent patients aged 16 years) [see Adverse Reactions ( 6.1 ), Clinical Pharmacology ( 12.3 ), Clinical Studies ( 14.1 )] . The safety and effectiveness of TAZVERIK in pediatric patients aged less than 16 years have not been established. Juvenile Animal Toxicity Data In a 13-week juvenile rat toxicology study, animals were dosed daily from post-natal day 7 to day 97 (approximately equivalent to neonate to adulthood). Tazemetostat resulted in: T-LBL at doses ≥50 mg/kg (approximately 2.8 times the adult human exposure at the 800 mg twice daily dose) Increased trabecular bone at doses ≥100 mg/kg (approximately 10 times the adult human exposure at the 800 mg twice daily dose) Increased body weight at doses ≥50 mg/kg (approximately equal to the adult human exposure at the 800 mg twice daily dose) Distended testicles in males at doses ≥50 mg/kg (approximately equal to the adult human exposure at the 800 mg twice daily dose) 8.5 Geriatric Use Clinical studies of TAZVERIK did not include sufficient numbers of patients with epithelioid sarcoma or relapsed or refractory follicular lymphoma aged 65 and over to determine whether they respond differently from younger subjects. 8.6 Renal Impairment No dose adjustment of TAZVERIK is recommended for patients with mild to severe renal impairment or end stage renal disease [see Clinical Pharmacology ( 12.3 )] . 8.7 Hepatic Impairment No dose adjustment of TAZVERIK is recommended for patients with mild hepatic impairment (total bilirubin > 1 to 1.5 times upper limit of normal [ULN] or AST > ULN). TAZVERIK has not been studied in patients with moderate (total bilirubin > 1.5 to 3 times ULN) or severe (total bilirubin > 3 times ULN) hepatic impairment [see Clinical Pharmacology ( 12.3 )]."],"dosage_and_administration_table":["
Table 1. Recommended Dose Reductions of TAZVERIK for Adverse Reactions
*Permanently discontinue TAZVERIK in patients who are unable to tolerate 400 mg orally twice daily.
Dose ReductionDosage
First600 mg orally twice daily
Second400 mg orally twice daily*
","
Table 2. Recommended Dosage Modifications of TAZVERIK for Adverse Reactions
Adverse ReactionSeverityDosage Modification
Neutropenia [see Adverse Reactions (6.1)]Neutrophil count less than 1 × 109/LWithhold until neutrophil count is greater than or equal to 1 × 109/L or baseline.For first occurrence, resume at same dose.For second and third occurrence, resume at reduced dose.Permanently discontinue after fourth occurrence.
Thrombocytopenia [see Adverse Reactions (6.1)]Platelet count less than 50 × 109/LWithhold until platelet count is greater than or equal to 75 × 109/L or baseline.For first and second occurrence, resume at reduced dose.Permanently discontinue after third occurrence.
Anemia [see Adverse Reactions (6.1)]Hemoglobin less than 8 g/dLWithhold until improvement to at least Grade 1 or baseline, then resume at same or reduced dose.
Other adverse reactions [see Adverse Reactions (6.1)]Grade 3Withhold until improvement to at least Grade 1 or baseline.For first and second occurrence, resume at reduced dose.Permanently discontinue after third occurrence.
Grade 4Withhold until improvement to at least Grade 1 or baseline.For first occurrence, resume at reduced dose.Permanently discontinue after second occurrence.
","
Table 3. Recommended Dose Reductions of TAZVERIK for Strong or Moderate CYP3A Inhibitors
Current DosageAdjusted Dosage
800 mg orally twice daily400 mg orally twice daily
600 mg orally twice daily400 mg for first dose and 200 mg for second dose
400 mg orally twice daily200 mg orally twice daily
"],"package_label_principal_display_panel":["Principal Display Panel - 200 mg Bottle Label NDC 72607-100-00 240 Tablets TAZVERIK ® (tazemetostat) tablets 200 mg Rx only Dispense the Medication Guide, attached or provided separately, to each patient pursuant to Federal Law. Epizyme Principal Display Panel - 200 mg Bottle Label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Dedicated carcinogenicity studies were not conducted with tazemetostat, but T-LBL, MDS, AML, and B-ALL have been reported clinically and T-LBL occurred in juvenile and adult rats after ~9 or more weeks of tazemetostat administration during 13-week toxicity studies. Based on nonclinical studies in rats, the risk of T-LBL appears to be greater with longer duration dosing. Tazemetostat did not cause genetic damage in a standard battery of studies including a screening and pivotal bacterial reverse mutation (Ames) assay, an in vitro micronucleus assessment in human peripheral blood lymphocytes, and an in vivo micronucleus assessment in rats after oral administration. Fertility and early embryonic development studies have not been conducted with tazemetostat; however, assessments of male and female reproductive organs were included in 4- and 13-week repeat-dose toxicity studies in rats and cynomolgus monkeys. Oral daily administration of tazemetostat did not result in any notable effects in the adult male and female reproductive organs [see Use in Specific Populations ( 8.3 )] ."]},"tags":[{"label":"Methyltransferase Inhibitor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Polycomb protein EED","category":"target"},{"label":"EED","category":"gene"},{"label":"EZH2","category":"gene"},{"label":"EZH1","category":"gene"},{"label":"L01XX72","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Active","category":"status"},{"label":"Epithelioid sarcoma","category":"indication"},{"label":"Follicular lymphoma","category":"indication"},{"label":"Epizyme Inc","category":"company"},{"label":"Approved 2020s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"317 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"310 reports"},{"date":"","signal":"DISEASE PROGRESSION","source":"FDA FAERS","actionTaken":"298 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"221 reports"},{"date":"","signal":"PRODUCT DOSE OMISSION ISSUE","source":"FDA FAERS","actionTaken":"194 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"117 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"109 reports"},{"date":"","signal":"DECREASED APPETITE","source":"FDA FAERS","actionTaken":"89 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"87 reports"},{"date":"","signal":"ASTHENIA","source":"FDA FAERS","actionTaken":"82 reports"}],"commonSideEffects":[{"effect":"Pain","drugRate":"≥20%","severity":"serious","_validated":true},{"effect":"Fatigue","drugRate":"≥20%","severity":"serious","_validated":true},{"effect":"Nausea","drugRate":"≥20%","severity":"serious","_validated":true},{"effect":"Decreased appetite","drugRate":"≥20%","severity":"serious","_validated":true},{"effect":"Vomiting","drugRate":"≥20%","severity":"serious","_validated":true},{"effect":"Constipation","drugRate":"≥20%","severity":"serious","_validated":true},{"effect":"Upper respiratory tract infection","drugRate":"≥20%","severity":"serious","_validated":true},{"effect":"Hemorrhage","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Dyspnea","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Headache","drugRate":"15%","severity":"common","_validated":true},{"effect":"Cough","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Diarrhea","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Weight decreased","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Thrombocytopenia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"General physical health deterioration","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Anemia","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Sepsis","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Pneumonia","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Second primary malignancy","drugRate":"6.1%","severity":"mild","_validated":true},{"effect":"Increased alanine aminotransferase (ALT)","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Increased aspartate aminotransferase (AST)","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3}],"specialPopulations":{"Lactation":"There are no animal or human data on the presence of tazemetostat in human milk or on its effects on the breastfed child or milk production. Because of the potential risk for serious adverse reactions from TAZVERIK in the breastfed child, advise women not to breastfeed during treatment with TAZVERIK and for one week after the final dose.","Pregnancy":"TAZVERIK can cause fetal harm when administered to pregnant women. There are no available data on TAZVERIK use in pregnant women to inform the drug-associated risk. Administration of tazemetostat to pregnant rats and rabbits during organogenesis resulted in dose-dependent increases in skeletal developmental abnormalities in both species beginning at maternal exposures approximately 1.5 times the adult human exposure [AUC0-45h] at the 800 mg twice daily dose. Advise pregnant women of the potential risk to fetus.","Geriatric use":"Clinical studies of TAZVERIK did not include sufficient numbers of patients with epithelioid sarcoma or relapsed or refactory follicular lymphoma aged 65 and over to determine whether they respond differently from younger subjects.","Paediatric use":"The safety and effectiveness of TAZVERIK have been established in pediatric patients aged 16 years and older (adolescents) with metastatic or locally advanced epithelioid sarcoma. Use of TAZVERIK for this indication is supported by evidence from adequate and well-controlled studies in adults (including adolescent patients aged 16 years) [see Adverse Reactions (6.1), Clinical Pharmacology (12.3), Clinical Studies (14.1)]."}},"trials":[],"aliases":[],"company":"Epizyme Inc","patents":[{"applNo":"N211723","source":"FDA Orange Book","status":"Active","expires":"Oct 16, 2035","useCode":"U-2736","territory":"US","drugProduct":false,"patentNumber":"9889138","drugSubstance":false},{"applNo":"N211723","source":"FDA Orange Book","status":"Active","expires":"Sep 12, 2031","useCode":"U-2736","territory":"US","drugProduct":false,"patentNumber":"10155002","drugSubstance":false},{"applNo":"N211723","source":"FDA Orange Book","status":"Active","expires":"Apr 11, 2033","useCode":"U-2737","territory":"US","drugProduct":false,"patentNumber":"10245269","drugSubstance":false},{"applNo":"N211723","source":"FDA Orange Book","status":"Active","expires":"Aug 22, 2034","useCode":"U-2736","territory":"US","drugProduct":false,"patentNumber":"9688665","drugSubstance":false},{"applNo":"N211723","source":"FDA Orange Book","status":"Active","expires":"Sep 12, 2031","useCode":"U-2736","territory":"US","drugProduct":false,"patentNumber":"9549931","drugSubstance":false},{"applNo":"N211723","source":"FDA Orange Book","status":"Active","expires":"Sep 12, 2031","useCode":"U-2736","territory":"US","drugProduct":false,"patentNumber":"9855275","drugSubstance":false},{"applNo":"N211723","source":"FDA Orange Book","status":"Active","expires":"Sep 12, 2031","useCode":"U-2736","territory":"US","drugProduct":false,"patentNumber":"10420775","drugSubstance":false},{"applNo":"N211723","source":"FDA Orange Book","status":"Active","expires":"Oct 16, 2035","useCode":"U-2736","territory":"US","drugProduct":false,"patentNumber":"10369155","drugSubstance":false},{"applNo":"N211723","source":"FDA Orange Book","status":"Active","expires":"Sep 12, 2031","useCode":"U-2736","territory":"US","drugProduct":true,"patentNumber":"11052093","drugSubstance":true},{"applNo":"N211723","source":"FDA Orange Book","status":"Active","expires":"Sep 12, 2031","useCode":"U-2852","territory":"US","drugProduct":false,"patentNumber":"8765732","drugSubstance":false},{"applNo":"N211723","source":"FDA Orange Book","status":"Active","expires":"Sep 12, 2031","useCode":"U-2852","territory":"US","drugProduct":false,"patentNumber":"9334527","drugSubstance":false},{"applNo":"N211723","source":"FDA Orange Book","status":"Active","expires":"Sep 12, 2031","useCode":"U-2852","territory":"US","drugProduct":false,"patentNumber":"9333217","drugSubstance":false},{"applNo":"N211723","source":"FDA Orange Book","status":"Active","expires":"Sep 12, 2031","useCode":"U-2852","territory":"US","drugProduct":false,"patentNumber":"8691507","drugSubstance":false},{"applNo":"N211723","source":"FDA Orange Book","status":"Active","expires":"Apr 11, 2033","useCode":"U-2852","territory":"US","drugProduct":true,"patentNumber":"9394283","drugSubstance":true},{"applNo":"N211723","source":"FDA Orange Book","status":"Active","expires":"Sep 12, 2031","useCode":"U-2852","territory":"US","drugProduct":false,"patentNumber":"9175331","drugSubstance":false},{"applNo":"N211723","source":"FDA Orange Book","status":"Active","expires":"Sep 12, 2031","useCode":"U-2852","territory":"US","drugProduct":false,"patentNumber":"8895245","drugSubstance":false},{"applNo":"N211723","source":"FDA Orange Book","status":"Active","expires":"Sep 12, 2031","useCode":"U-2851","territory":"US","drugProduct":false,"patentNumber":"9949999","drugSubstance":false},{"applNo":"N211723","source":"FDA Orange Book","status":"Active","expires":"Sep 12, 2031","useCode":"U-2853","territory":"US","drugProduct":false,"patentNumber":"12161645","drugSubstance":false},{"applNo":"N211723","source":"FDA Orange Book","status":"Active","expires":"Jun 12, 2034","useCode":"U-2736","territory":"US","drugProduct":false,"patentNumber":"12162865","drugSubstance":false},{"applNo":"N211723","source":"FDA Orange Book","status":"Active","expires":"Sep 12, 2031","useCode":"U-2736","territory":"US","drugProduct":false,"patentNumber":"12168016","drugSubstance":false},{"applNo":"N211723","source":"FDA Orange Book","status":"Active","expires":"May 3, 2038","useCode":"U-2736","territory":"US","drugProduct":false,"patentNumber":"12168014","drugSubstance":false},{"applNo":"N211723","source":"FDA Orange Book","status":"Active","expires":"Apr 11, 2033","useCode":"U-2852","territory":"US","drugProduct":false,"patentNumber":"11491163","drugSubstance":false},{"applNo":"N211723","source":"FDA Orange Book","status":"Active","expires":"Dec 19, 2035","useCode":"","territory":"US","drugProduct":true,"patentNumber":"10786511","drugSubstance":false},{"applNo":"N211723","source":"FDA Orange Book","status":"Active","expires":"Sep 12, 2031","useCode":"","territory":"US","drugProduct":true,"patentNumber":"9090562","drugSubstance":true},{"applNo":"N211723","source":"FDA Orange Book","status":"Active","expires":"Sep 12, 2031","useCode":"","territory":"US","drugProduct":true,"patentNumber":"12168015","drugSubstance":true},{"applNo":"N211723","source":"FDA Orange Book","status":"Active","expires":"Jan 23, 2034","useCode":"","territory":"US","drugProduct":true,"patentNumber":"8410088","drugSubstance":true},{"applNo":"N211723","source":"FDA Orange Book","status":"Active","expires":"Apr 11, 2033","useCode":"","territory":"US","drugProduct":true,"patentNumber":"10821113","drugSubstance":true}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=tazemetostat","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:53:29.378104+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:53:25.645740+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Tazemetostat","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:53:39.497657+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:53:35.886076+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:53:22.813264+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tazemetostat","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:53:38.454850+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:53:22.222487+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:54:29.760041+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:53:22.222516+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:53:39.966054+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Histone-lysine N-methyltransferase EZH2 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:53:39.497590+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4594260/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:53:39.158812+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA211723","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:53:22.222520+00:00"}},"allNames":"tazverik","offLabel":[],"synonyms":["tazemetostat","tazemetostat hydrobromide","tazverik","EPZ-6438","EZ438"],"timeline":[{"date":"2020-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from EPIZYME INC to Epizyme Inc"},{"date":"2021-06-23","type":"positive","source":"DrugCentral","milestone":"PMDA approval (EISAI Co., Ltd.)"},{"date":"2027-01-23","type":"negative","source":"FDA Orange Book","milestone":"ODE-299 exclusivity expires"},{"date":"2027-06-18","type":"negative","source":"FDA Orange Book","milestone":"ODE-314 exclusivity expires"},{"date":"2031-09-12","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 11052093 expires"},{"date":"2033-04-11","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 9394283 expires"},{"date":"2034-01-23","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 8410088 expires"}],"aiSummary":"Tazverik (tazemetostat) is a small molecule methyltransferase inhibitor developed by Epizyme Inc, targeting the Polycomb protein EED. It was FDA-approved in 2020 for the treatment of epithelioid sarcoma and follicular lymphoma. Tazverik is a patented medication with no generic manufacturers available. The drug has a half-life of approximately 3.1 hours. Key safety considerations include its potential to cause infections, anemia, and thrombocytopenia.","brandName":"Tazverik","ecosystem":[{"indication":"Epithelioid sarcoma","otherDrugs":[],"globalPrevalence":null},{"indication":"Follicular lymphoma","otherDrugs":[{"name":"copanlisib","slug":"copanlisib","company":"Bayer Healthcare Pharms"},{"name":"interferon alfa-2b","slug":"interferon-alfa-2b","company":"Schering"},{"name":"lenalidomide","slug":"lenalidomide","company":"Celgene"},{"name":"rituximab","slug":"rituximab","company":"Genentech"}],"globalPrevalence":120000}],"mechanism":{"target":"Polycomb protein EED","novelty":"Follow-on","targets":[{"gene":"EED","source":"DrugCentral","target":"Polycomb protein EED","protein":"Polycomb protein EED"},{"gene":"EZH2","source":"DrugCentral","target":"Histone-lysine N-methyltransferase EZH2","protein":"Histone-lysine N-methyltransferase EZH2"},{"gene":"EZH1","source":"DrugCentral","target":"Histone-lysine N-methyltransferase EZH1","protein":"Histone-lysine N-methyltransferase EZH1"}],"moaClass":"Methyltransferase Inhibitors","modality":"Small Molecule","drugClass":"Methyltransferase Inhibitor","explanation":"Tazemetostat is an inhibitor of the methyltransferase, EZH2, and some EZH2 gain-of-function mutations including Y646X, A682G, and A692V. Tazemetostat also inhibited EZH1 with half-maximal inhibitory concentration (IC50) of 392 nM, approximately 36 times higher than the IC50 for inhibition of EZH2.The most well-characterized function of EZH2 is as the catalytic subunit of the polycomb repressive complex (PRC2), catalyzing mono-, di-, and trimethylation of lysine 27 of histone H3. Trimethylation of histone H3 leads to transcriptional repression.SWItch/Sucrose Non-Fermentable (SWI/SNF) complexes can antagonize PRC2 function in the regulation of the expression of certain genes of patients with epithelioid sarcoma. Preclinical in vitro and in vivo models with the loss or dysfunction of certain SWI/SNF complex members (e.g., integrase interactor [INI1/SNF5/SMARCB1/BAF47], SMARCA4, and SMARCA2) can lead to aberrant EZH2 activity or expression and resulting oncogenic","oneSentence":"Tazverik works by blocking the action of the EED protein, which is involved in the regulation of gene expression.","technicalDetail":"Tazverik specifically inhibits the methyltransferase activity of the EED subunit of the Polycomb repressive complex 2 (PRC2), leading to the loss of histone H3 lysine 27 trimethylation (H3K27me3) marks and subsequent disruption of gene silencing."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Tazemetostat","title":"Tazemetostat","extract":"Tazemetostat, sold under the brand name Tazverik, is a medication used for the treatment of adults and adolescents aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.","wiki_history":"==History==\nThe U.S. Food and Drug Administration (FDA) approved tazemetostat in January 2020,\n\nThe FDA granted the application for tazemetostat accelerated approval and orphan drug designation. Ipsen cited the advice from the data monitoring committee who observed adverse events of secondary hematologic malignancies in the [https://clinicaltrials.gov/study/NCT04224493 SYMPHONY-1] study. Ipsen's partner in China, Hutchmed, also withdrew tazemetostat in mainland China, Hong Kong and Macau."},"commercial":{"launchDate":"2020","_launchSource":"DrugCentral (FDA 2020-01-23, EPIZYME INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5380","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=tazemetostat","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tazemetostat","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Tazemetostat","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T02:22:40.611208","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:54:31.496347+00:00","fieldsConflicting":12,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"asparaginase","drugSlug":"asparaginase","fdaApproval":"1994-02-01","relationship":"same-class"},{"drugName":"altretamine","drugSlug":"altretamine","fdaApproval":"1990-12-26","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"hydroxycarbamide","drugSlug":"hydroxycarbamide","fdaApproval":"1967-12-07","relationship":"same-class"},{"drugName":"pentostatin","drugSlug":"pentostatin","fdaApproval":"1991-10-11","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"masoprocol","drugSlug":"masoprocol","fdaApproval":"1992-09-04","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"mitotane","drugSlug":"mitotane","fdaApproval":"1970-07-08","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"pegaspargase","drugSlug":"pegaspargase","fdaApproval":"1994-02-01","relationship":"same-class"},{"drugName":"arsenic trioxide","drugSlug":"arsenic-trioxide","fdaApproval":"2000-09-25","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"denileukin diftitox","drugSlug":"denileukin-diftitox","fdaApproval":"1999-02-05","relationship":"same-class"},{"drugName":"celecoxib","drugSlug":"celecoxib","fdaApproval":"1998-12-31","patentExpiry":"May 27, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"anagrelide","drugSlug":"anagrelide","fdaApproval":"1997-03-14","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"omacetaxine mepesuccinate","drugSlug":"omacetaxine-mepesuccinate","fdaApproval":"2012-10-26","patentExpiry":"Oct 26, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"eribulin","drugSlug":"eribulin","fdaApproval":"2010-11-15","patentExpiry":"Jul 8, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"aflibercept","drugSlug":"aflibercept","fdaApproval":"2011-11-18","relationship":"same-class"},{"drugName":"venetoclax","drugSlug":"venetoclax","fdaApproval":"2016-04-11","patentExpiry":"Sep 6, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"enasidenib","drugSlug":"enasidenib","fdaApproval":"2017-08-01","patentExpiry":"Sep 16, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ivosidenib","drugSlug":"ivosidenib","fdaApproval":"2018-07-20","patentExpiry":"Oct 18, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"selinexor","drugSlug":"selinexor","fdaApproval":"2019-07-03","patentExpiry":"Jul 3, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"tagraxofusp","drugSlug":"tagraxofusp","fdaApproval":"2018-12-21","relationship":"same-class"},{"drugName":"lurbinectedin","drugSlug":"lurbinectedin","fdaApproval":"2020-06-15","patentExpiry":"May 29, 2040","patentStatus":"Patent protected","relationship":"same-class"}],"exclusivity":[{"code":"ODE-299","date":"Jan 23, 2027"},{"code":"ODE-314","date":"Jun 18, 2027"}],"genericName":"tazemetostat","indications":{"approved":[{"id":"tazemetostat-epithelioid-sarcoma","name":"Epithelioid Sarcoma","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection","diagnosticRequired":null,"brandNameForIndication":"Tazverik"},{"id":"tazemetostat-relapsed-or-refractory-follicu","name":"Relapsed or Refractory Follicular Lymphoma with EZH2 Mutation","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation and who have received at least 2 prior systemic therapies","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation and who have received at least 2 prior systemic therapies","diagnosticRequired":"EZH2 mutation as detected by an FDA-approved test","brandNameForIndication":"Tazverik"},{"id":"tazemetostat-relapsed-or-refractory-follicu","name":"Relapsed or Refractory Follicular Lymphoma without Satisfactory Alternatives","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options","diagnosticRequired":null,"brandNameForIndication":"Tazverik"}],"offLabel":[],"pipeline":[]},"currentOwner":"Epizyme Inc","drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"asparaginase","brandName":"asparaginase","genericName":"asparaginase","approvalYear":"1994","relationship":"same-class"},{"drugId":"altretamine","brandName":"altretamine","genericName":"altretamine","approvalYear":"1990","relationship":"same-class"},{"drugId":"hydroxycarbamide","brandName":"hydroxycarbamide","genericName":"hydroxycarbamide","approvalYear":"1967","relationship":"same-class"},{"drugId":"pentostatin","brandName":"pentostatin","genericName":"pentostatin","approvalYear":"1991","relationship":"same-class"},{"drugId":"masoprocol","brandName":"masoprocol","genericName":"masoprocol","approvalYear":"1992","relationship":"same-class"},{"drugId":"mitotane","brandName":"mitotane","genericName":"mitotane","approvalYear":"1970","relationship":"same-class"},{"drugId":"pegaspargase","brandName":"pegaspargase","genericName":"pegaspargase","approvalYear":"1994","relationship":"same-class"},{"drugId":"arsenic-trioxide","brandName":"arsenic trioxide","genericName":"arsenic trioxide","approvalYear":"2000","relationship":"same-class"},{"drugId":"denileukin-diftitox","brandName":"denileukin diftitox","genericName":"denileukin diftitox","approvalYear":"1999","relationship":"same-class"},{"drugId":"celecoxib","brandName":"celecoxib","genericName":"celecoxib","approvalYear":"1998","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03854474","phase":"PHASE1,PHASE2","title":"Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-11-18","conditions":["Locally Advanced Urothelial Carcinoma","Metastatic Urothelial Carcinoma","Stage III Bladder Cancer AJCC v8","Stage IV Bladder Cancer AJCC v8"],"enrollment":30,"completionDate":"2026-06-30"},{"nctId":"NCT03348631","phase":"PHASE2","title":"Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-01","conditions":["Recurrent Endometrial Endometrioid Adenocarcinoma","Recurrent Malignant Uterine Corpus Neoplasm","Recurrent Ovarian Carcinoma","Recurrent Ovarian Clear Cell Adenocarcinoma","Recurrent Ovarian Endometrioid Adenocarcinoma"],"enrollment":62,"completionDate":"2027-02-12"},{"nctId":"NCT05353439","phase":"PHASE1","title":"Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-07-27","conditions":["Extensive Stage Lung Small Cell Carcinoma","Limited Stage Lung Small Cell Carcinoma","Platinum-Resistant Lung Small Cell Carcinoma","Platinum-Sensitive Lung Small Cell Carcinoma","Recurrent Extensive Stage Lung Small Cell Carcinoma","Recurrent Lung Small Cell Carcinoma"],"enrollment":18,"completionDate":"2027-03-13"},{"nctId":"NCT05627245","phase":"PHASE1","title":"Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-01","conditions":["Recurrent B-Cell Non-Hodgkin Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","Recurrent Follicular Lymphoma","Recurrent Non-Hodgkin Lymphoma","Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","Recurrent T-Cell Non-Hodgkin Lymphoma","Recurrent Transformed Non-Hodgkin Lymphoma","Refractory B-Cell Non-Hodgkin Lymphoma","Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","Refractory Follicular Lymphoma","Refractory Non-Hodgkin Lymphoma","Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","Refractory T-Cell Non-Hodgkin Lymphoma","Refractory Transformed Non-Hodgkin Lymphoma"],"enrollment":48,"completionDate":"2026-09-01"},{"nctId":"NCT04557956","phase":"PHASE1,PHASE2","title":"Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-19","conditions":["Clinical Stage IV Cutaneous Melanoma AJCC v8","Metastatic Melanoma"],"enrollment":16,"completionDate":"2027-03-11"},{"nctId":"NCT05023655","phase":"PHASE2","title":"Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation","status":"TERMINATED","sponsor":"Prisma Health-Upstate","startDate":"2022-01-06","conditions":["Solid Tumor","ARID1A Gene Mutation"],"enrollment":20,"completionDate":"2026-03-06"},{"nctId":"NCT05627232","phase":"PHASE1","title":"Tazemetostat and Palbociclib With CPX-351for R/R AML","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-08-28","conditions":["Recurrent Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia"],"enrollment":24,"completionDate":"2029-01"},{"nctId":"NCT04179864","phase":"PHASE1,PHASE2","title":"A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer","status":"TERMINATED","sponsor":"Epizyme, Inc.","startDate":"2019-11-18","conditions":["Metastatic Prostate Cancer","Metastatic Castration-resistant Prostate Cancer"],"enrollment":102,"completionDate":"2024-11-04"},{"nctId":"NCT04705818","phase":"PHASE2","title":"Combining Epigenetic And Immune Therapy to Beat Cancer.","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2021-07-23","conditions":["Advanced Solid Tumor","Advanced Colorectal Carcinoma","Advanced Soft-tissue Sarcoma","Advanced Pancreatic Adenocarcinoma","Adult Solid Tumor"],"enrollment":164,"completionDate":"2025-07-17"},{"nctId":"NCT07282548","phase":"","title":"Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies","status":"NOT_YET_RECRUITING","sponsor":"Ipsen","startDate":"2026-06","conditions":["Follicular Lymphoma"],"enrollment":63,"completionDate":"2031-06-30"},{"nctId":"NCT04224493","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.","status":"RECRUITING","sponsor":"Epizyme, Inc.","startDate":"2020-06-11","conditions":["Relapsed/Refractory Follicular Lymphoma","Follicular Lymphoma","Refractory Follicular Lymphoma"],"enrollment":612,"completionDate":"2029-03-01"},{"nctId":"NCT05551936","phase":"PHASE1,PHASE2","title":"A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vaishalee Kenkre","startDate":"2023-01-26","conditions":["Follicular Lymphoma"],"enrollment":42,"completionDate":"2027-05"},{"nctId":"NCT07407283","phase":"PHASE1,PHASE2","title":"A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2026-03","conditions":["Prostate Cancer"],"enrollment":100,"completionDate":"2028-04"},{"nctId":"NCT03155620","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-07-31","conditions":["Advanced Malignant Solid Neoplasm","Ann Arbor Stage III Non-Hodgkin Lymphoma","Ann Arbor Stage IV Non-Hodgkin Lymphoma","Histiocytic Sarcoma","Juvenile Xanthogranuloma","Langerhans Cell Histiocytosis","Malignant Glioma","Recurrent Childhood Rhabdomyosarcoma","Recurrent Ependymoma","Recurrent Ewing Sarcoma","Recurrent Glioma","Recurrent Hepatoblastoma","Recurrent Langerhans Cell Histiocytosis","Recurrent Malignant Germ Cell Tumor","Recurrent Malignant Solid Neoplasm","Recurrent Medulloblastoma","Recurrent Neuroblastoma","Recurrent Non-Hodgkin Lymphoma","Recurrent Osteosarcoma","Recurrent Peripheral Primitive Neuroectodermal Tumor","Recurrent Primary Central Nervous System Neoplasm","Recurrent Rhabdoid Tumor","Recurrent Soft Tissue Sarcoma","Refractory Ewing Sarcoma","Refractory Glioma","Refractory Hepatoblastoma","Refractory Langerhans Cell Histiocytosis","Refractory Malignant Germ Cell Tumor","Refractory Malignant Solid Neoplasm","Refractory Medulloblastoma","Refractory Neuroblastoma","Refractory Non-Hodgkin Lymphoma","Refractory Osteosarcoma","Refractory Peripheral Primitive Neuroectodermal Tumor","Refractory Primary Central Nervous System Neoplasm","Refractory Rhabdoid Tumor","Refractory Rhabdomyosarcoma","Rhabdoid Tumor","Stage III Osteosarcoma AJCC v7","Stage III Soft Tissue Sarcoma AJCC v7","Stage IV Osteosarcoma AJCC v7","Stage IV Soft Tissue Sarcoma AJCC v7","Stage IVA Osteosarcoma AJCC v7","Stage IVB Osteosarcoma AJCC v7","Wilms Tumor"],"enrollment":1376,"completionDate":"2027-01-06"},{"nctId":"NCT04917042","phase":"PHASE2","title":"Tazemetostat in Malignant Peripheral Nerve Sheath Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2021-08-25","conditions":["Peripheral Nerve Sheath Tumor"],"enrollment":10,"completionDate":"2026-04"},{"nctId":"NCT06068881","phase":"PHASE2","title":"A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an \"EZH2 Gain-of-function\" Genetic Mutation","status":"WITHDRAWN","sponsor":"Epizyme, Inc.","startDate":"2025-09-02","conditions":["Follicular Lymphoma","Refractory Follicular Lymphoma"],"enrollment":0,"completionDate":"2029-04-06"},{"nctId":"NCT04241835","phase":"PHASE1","title":"A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function","status":"RECRUITING","sponsor":"Epizyme, Inc.","startDate":"2020-01-15","conditions":["Hepatic Impairment","Advanced Malignant Solid Tumor"],"enrollment":24,"completionDate":"2026-04-30"},{"nctId":"NCT05467748","phase":"PHASE1,PHASE2","title":"EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2025-12-08","conditions":["Non Small Cell Lung Cancer"],"enrollment":66,"completionDate":"2029-12-07"},{"nctId":"NCT06575686","phase":"PHASE2","title":"Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","status":"SUSPENDED","sponsor":"City of Hope Medical Center","startDate":"2025-03-11","conditions":["Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3a Follicular Lymphoma","Refractory Grade 1 Follicular Lymphoma","Refractory Grade 2 Follicular Lymphoma","Refractory Grade 3a Follicular Lymphoma"],"enrollment":33,"completionDate":"2028-07-16"},{"nctId":"NCT06242834","phase":"PHASE2","title":"Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2024-09-30","conditions":["B-Cell Non-Hodgkin Lymphoma"],"enrollment":32,"completionDate":"2028-11-24"},{"nctId":"NCT04204941","phase":"PHASE1","title":"Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma","status":"TERMINATED","sponsor":"Epizyme, Inc.","startDate":"2019-12-19","conditions":["Advanced Soft-tissue Sarcoma","Advanced Epithelioid Sarcoma"],"enrollment":25,"completionDate":"2024-06-14"},{"nctId":"NCT06692452","phase":"PHASE2","title":"Tazemetostat Plus CHOP in 1L T-cell Lymphoma","status":"SUSPENDED","sponsor":"Eric Jacobsen, MD","startDate":"2024-12-24","conditions":["Lymphoma","Peripheral T Cell Lymphoma","Angioimmunoblastic T-cell Lymphoma","Enteropathy-Associated T-Cell Lymphoma","Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma"],"enrollment":24,"completionDate":"2032-10-01"},{"nctId":"NCT05228158","phase":"","title":"A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Co., Ltd.","startDate":"2021-08-16","conditions":["Lymphoma, Follicular"],"enrollment":145,"completionDate":"2028-03-31"},{"nctId":"NCT06824701","phase":"PHASE1","title":"Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Utah","startDate":"2025-09-12","conditions":["Relapsed or Refractory B-cell Non-Hodgkin Lymphoma"],"enrollment":24,"completionDate":"2033-01"},{"nctId":"NCT02875548","phase":"PHASE1,PHASE2","title":"A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study","status":"COMPLETED","sponsor":"Epizyme, Inc.","startDate":"2016-08-30","conditions":["Diffuse Large B-cell Lymphoma (DLBCL)","Follicular Lymphoma (FL)","Synovial Sarcoma","Epitheliod Sarcoma (ES)","Mesothelioma","Advanced Solid Tumors","Renal Medullary Carcinoma","Non-Hodgkin Lymphoma (NHL)"],"enrollment":58,"completionDate":"2025-09-26"},{"nctId":"NCT05890352","phase":"PHASE2","title":"Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2023-09-26","conditions":["Grade 3b Follicular Lymphoma","High Grade B-Cell Lymphoma","High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements","Recurrent Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Transformed Non-Hodgkin Lymphoma"],"enrollment":227,"completionDate":"2029-01"},{"nctId":"NCT07209163","phase":"PHASE1,PHASE2","title":"Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-10","conditions":["Peripheral T Cell Lymphoma"],"enrollment":48,"completionDate":"2027-03"},{"nctId":"NCT05407441","phase":"PHASE1,PHASE2","title":"Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors","status":"RECRUITING","sponsor":"Susan Chi, MD","startDate":"2023-08-10","conditions":["Atypical Teratoid Rhabdoid Tumor","INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors","SMARCA4-deficient Primary CNS Malignant Tumors","Malignant Rhabdoid Tumor (MRT)","Rhabdoid Tumor of the Kidney (RTK)","Epithelioid Sarcoma","Chordoma"],"enrollment":49,"completionDate":"2029-02-01"},{"nctId":"NCT05983965","phase":"PHASE1","title":"Study of Tazemetostat in Lymphoid Malignancies","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2024-09-05","conditions":["T-cell Lymphoma"],"enrollment":30,"completionDate":"2029-12"},{"nctId":"NCT05372354","phase":"PHASE1,PHASE2","title":"A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2022-10-18","conditions":["Multiple Myeloma"],"enrollment":260,"completionDate":"2026-10-12"},{"nctId":"NCT05934838","phase":"PHASE1","title":"A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2023-10-04","conditions":["Follicular Lymphoma","B-Cell Lymphoma","Mantle Cell Lymphoma","Diffuse Large B Cell Lymphoma"],"enrollment":15,"completionDate":"2031-09"},{"nctId":"NCT02601950","phase":"PHASE2","title":"A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Epizyme, Inc.","isPivotal":true,"startDate":"2015-12-22","conditions":["Malignant Rhabdoid Tumors (MRT)","Rhabdoid Tumors of the Kidney (RTK)","Atypical Teratoid Rhabdoid Tumors (ATRT)","Selected Tumors With Rhabdoid Features","Synovial Sarcoma","INI1-negative Tumors","Malignant Rhabdoid Tumor of Ovary","Renal Medullary Carcinoma","Epithelioid Sarcoma","Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval)","Any Solid Tumor With an EZH2 GOF Mutation"],"enrollment":267,"completionDate":"2024-02-26"},{"nctId":"NCT04846478","phase":"PHASE1","title":"Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-06-28","conditions":["Metastatic Prostate Cancer","Metastatic Castration-resistant Prostate Cancer"],"enrollment":35,"completionDate":"2026-09-30"},{"nctId":"NCT05994235","phase":"PHASE2","title":"Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2023-11-01","conditions":["Follicular Lymphoma"],"enrollment":50,"completionDate":"2033-10"},{"nctId":"NCT05618366","phase":"PHASE1","title":"Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2023-06-07","conditions":["Lymphoma, Non-Hodgkin","Diffuse Large B Cell Lymphoma","Follicular Lymphoma"],"enrollment":38,"completionDate":"2028-12"},{"nctId":"NCT04537715","phase":"PHASE1","title":"Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels","status":"COMPLETED","sponsor":"Epizyme, Inc.","startDate":"2020-04-23","conditions":["All Malignancies","Advanced Malignancies","Hematologic Malignancy","Solid Tumor","Follicular Lymphoma (FL)","Non-Hodgkin Lymphoma (NHL)","Diffuse Large B-Cell Lymphoma (DLBCL)","Epithelioid Sarcoma (ES)","Synovial Sarcoma","Renal Medullary Carcinoma","Mesothelioma","Rhabdoid Tumor"],"enrollment":42,"completionDate":"2023-04-03"},{"nctId":"NCT03213665","phase":"PHASE2","title":"Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-11-13","conditions":["Advanced Malignant Solid Neoplasm","Ann Arbor Stage III Hodgkin Lymphoma","Ann Arbor Stage III Non-Hodgkin Lymphoma","Ann Arbor Stage IV Hodgkin Lymphoma","Ann Arbor Stage IV Non-Hodgkin Lymphoma","Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","Low Grade Glioma","Recurrent Ependymoma","Recurrent Ewing Sarcoma","Recurrent Glioma","Recurrent Hepatoblastoma","Recurrent Hodgkin Lymphoma","Recurrent Langerhans Cell Histiocytosis","Recurrent Malignant Germ Cell Tumor","Recurrent Malignant Glioma","Recurrent Malignant Solid Neoplasm","Recurrent Medulloblastoma","Recurrent Neuroblastoma","Recurrent Non-Hodgkin Lymphoma","Recurrent Osteosarcoma","Recurrent Peripheral Primitive Neuroectodermal Tumor","Recurrent Primary Central Nervous System Neoplasm","Recurrent Rhabdoid Tumor","Recurrent Rhabdomyosarcoma","Recurrent Soft Tissue Sarcoma","Refractory Hodgkin Lymphoma","Refractory Langerhans Cell Histiocytosis","Refractory Malignant Germ Cell Tumor","Refractory Malignant Glioma","Refractory Malignant Solid Neoplasm","Refractory Medulloblastoma","Refractory Neuroblastoma","Refractory Non-Hodgkin Lymphoma","Refractory Osteosarcoma","Refractory Peripheral Primitive Neuroectodermal Tumor","Refractory Rhabdoid Tumor","Refractory Soft Tissue Sarcoma","Rhabdoid Tumor","Stage III Soft Tissue Sarcoma AJCC v7","Stage IV Soft Tissue Sarcoma AJCC v7","Wilms Tumor"],"enrollment":20,"completionDate":"2024-12-31"},{"nctId":"NCT05467943","phase":"PHASE2","title":"Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma","status":"COMPLETED","sponsor":"Hutchmed","startDate":"2022-07-29","conditions":["Relapsed/Refractory Follicular Lymphoma With EZH2"],"enrollment":42,"completionDate":"2024-11-30"},{"nctId":"NCT05713110","phase":"PHASE2","title":"A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma","status":"COMPLETED","sponsor":"Hutchmed","startDate":"2023-02-13","conditions":["Relapsed/Refractory Lymphoma"],"enrollment":61,"completionDate":"2024-12-31"},{"nctId":"NCT02889523","phase":"PHASE1,PHASE2","title":"Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2016-10","conditions":["Lymphoma","DLBCL","Follicular Lymphoma"],"enrollment":214,"completionDate":"2026-04"},{"nctId":"NCT02601937","phase":"PHASE1","title":"EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma","status":"COMPLETED","sponsor":"Epizyme, Inc.","startDate":"2016-01-07","conditions":["Rhabdoid Tumors","INI1-negative Tumors","Synovial Sarcoma","Malignant Rhabdoid Tumor of Ovary"],"enrollment":109,"completionDate":"2021-10-22"},{"nctId":"NCT04225429","phase":"","title":"Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma","status":"NO_LONGER_AVAILABLE","sponsor":"Epizyme, Inc.","startDate":"","conditions":["Epithelioid Sarcoma"],"enrollment":0,"completionDate":""},{"nctId":"NCT01897571","phase":"PHASE1,PHASE2","title":"Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL","status":"COMPLETED","sponsor":"Epizyme, Inc.","isPivotal":true,"startDate":"2013-06-13","conditions":["B-cell Lymphomas (Phase 1)","Advanced Solid Tumors (Phase 1)","Diffuse Large B-cell Lymphoma (Phase 2)","Follicular Lymphoma (Phase 2)","Transformed Follicular Lymphoma","Primary Mediastinal Large B-Cell Lymphoma"],"enrollment":400,"completionDate":"2021-11-02"},{"nctId":"NCT04762160","phase":"PHASE2","title":"SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma","status":"TERMINATED","sponsor":"Epizyme, Inc.","startDate":"2020-12-15","conditions":["Follicular Lymphoma"],"enrollment":5,"completionDate":"2022-03-22"},{"nctId":"NCT03874455","phase":"","title":"Tazemetostat Expanded Access Program for Adults With Solid Tumors","status":"NO_LONGER_AVAILABLE","sponsor":"Epizyme, Inc.","startDate":"","conditions":["Epithelioid Sarcoma (Ex-US Only)","Spindle Cell Sarcoma","Sinonasal Carcinoma","Small Cell Carcinoma of the Ovary Hypercalcemic Type","Thoracic Sarcoma","Poorly Differentiated Chordoma","ATRT","Malignant Rhabdoid Tumor of Kidney","Malignant Rhabdoid Tumor of Ovary","Malignant Rhabdoid Tumor","Myxoid Spindle Cell Sarcoma","Epithelioid Malignant Peripheral Nerve Sheath Tumor","Chondrosarcoma","Renal Cell Carcinoma","Myoepithelial Carcinoma","Synovial Sarcoma","Renal Medullary Carcinoma","Malignant Mesothelioma","Desmoplastic Small Round Cell Tumor (DSRCT)","Intramedullary Spinal Cord Schwannomatosis"],"enrollment":0,"completionDate":""},{"nctId":"NCT03010982","phase":"PHASE1","title":"Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors","status":"COMPLETED","sponsor":"Epizyme, Inc.","startDate":"2018-06-20","conditions":["Diffuse Large B Cell Lymphoma","Primary Mediastinal Lymphoma","Mantle-Cell Lymphoma","Follicular Lymphoma","Marginal Zone Lymphoma","Advanced Solid Tumors"],"enrollment":3,"completionDate":"2019-01-08"},{"nctId":"NCT04624113","phase":"PHASE1","title":"Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2021-04-14","conditions":["Head and Neck Squamous Cell Carcinoma"],"enrollment":13,"completionDate":"2024-02-17"},{"nctId":"NCT05567679","phase":"EARLY_PHASE1","title":"A Study of Tazemetostat (Tazverik) Before Prostatectomy in Men With Prostate Cancer","status":"WITHDRAWN","sponsor":"Edwin Posadas, MD","startDate":"2023-12","conditions":["Prostate Cancer"],"enrollment":0,"completionDate":"2025-12"},{"nctId":"NCT05205252","phase":"PHASE1,PHASE2","title":"A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.","status":"WITHDRAWN","sponsor":"Epizyme, Inc.","startDate":"2021-12-22","conditions":["Relapsed Hematologic Malignancy","Refractory Hematologic Malignancy"],"enrollment":0,"completionDate":"2023-07-05"},{"nctId":"NCT05604417","phase":"PHASE1,PHASE2","title":"Zandelisib + Tazemetostat in R/R Follicular Lymphoma","status":"WITHDRAWN","sponsor":"Jacob Soumerai, MD","startDate":"2023-01","conditions":["Relapsed Follicular Lymphoma","Refractory Follicular Lymphoma"],"enrollment":0,"completionDate":"2026-12-01"},{"nctId":"NCT03028103","phase":"PHASE1","title":"Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients","status":"COMPLETED","sponsor":"Epizyme, Inc.","startDate":"2017-03-27","conditions":["Diffuse Large B Cell Lymphoma","Primary Mediastinal Lymphoma","Mantle Cell Lymphoma","Advanced Solid Tumor","Marginal Zone Lymphoma"],"enrollment":32,"completionDate":"2019-11-29"},{"nctId":"NCT05152459","phase":"PHASE1,PHASE2","title":"Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2023-05-01","conditions":["Recurrent Follicular Lymphoma","Refractory Follicular Lymphoma"],"enrollment":0,"completionDate":"2024-12-15"},{"nctId":"NCT05774886","phase":"PHASE1","title":"Implantable Microdevice for TNBC - Pilot Study","status":"WITHDRAWN","sponsor":"Dana-Farber Cancer Institute","startDate":"2023-05","conditions":["Triple Negative Breast Cancer","Breast Cancer Stage II","Breast Cancer Stage III","Breast Cancer","Early Stage Triple-Negative Breast Carcinoma","Breast Neoplasms","Breast Carcinoma"],"enrollment":0,"completionDate":"2028-09-01"},{"nctId":"NCT05151588","phase":"PHASE2","title":"Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Dr. Victor H.F. Lee","startDate":"2023-09-01","conditions":["Sinonasal Carcinoma"],"enrollment":30,"completionDate":"2027-08-31"},{"nctId":"NCT03456726","phase":"PHASE2","title":"Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2018-04-09","conditions":["Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma"],"enrollment":20,"completionDate":"2021-12-17"},{"nctId":"NCT03009344","phase":"PHASE1","title":"A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2017-01-10","conditions":["Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma"],"enrollment":7,"completionDate":"2020-06-17"},{"nctId":"NCT05018975","phase":"PHASE2","title":"Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection","status":"WITHDRAWN","sponsor":"Loma Linda University","startDate":"2022-01","conditions":["COVID-19 Acute Respiratory Distress Syndrome","Cytokine Release Syndrome"],"enrollment":0,"completionDate":"2023-09-21"},{"nctId":"NCT02860286","phase":"PHASE2","title":"Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma","status":"COMPLETED","sponsor":"Epizyme, Inc.","startDate":"2016-07","conditions":["Mesothelioma","BAP1 Loss of Function"],"enrollment":74,"completionDate":"2019-05"},{"nctId":"NCT03217253","phase":"PHASE1","title":"Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2018-03-16","conditions":["Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma","Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma","Metastatic Malignant Solid Neoplasm","Stage III Hepatocellular Carcinoma AJCC v7","Stage IIIA Hepatocellular Carcinoma AJCC v7","Stage IIIB Hepatocellular Carcinoma AJCC v7","Stage IIIC Hepatocellular Carcinoma AJCC v7","Stage IV Hepatocellular Carcinoma AJCC v7","Stage IVA Hepatocellular Carcinoma AJCC v7","Stage IVB Hepatocellular Carcinoma AJCC v7","Unresectable Solid Neoplasm"],"enrollment":0,"completionDate":"2019-09-19"},{"nctId":"NCT02220842","phase":"PHASE1","title":"A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-12-18","conditions":["Lymphoma"],"enrollment":96,"completionDate":"2020-01-21"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"pivotalTrials":["NCT02601950","NCT01897571"],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET, FILM COATED","route":"ORAL","productName":"TAZVERIK"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"329834","NDDF":"018265","UNII":"Q40W93WPE1","VANDF":"4039121","INN_ID":"9963","RXNORM":"2274378","UMLSCUI":"C4086895","chemblId":"CHEMBL4594260","ChEMBL_ID":"CHEMBL3414621","KEGG_DRUG":"D11444","DRUGBANK_ID":"DB12887","PUBCHEM_CID":"66558664","SNOMEDCT_US":"840405005","IUPHAR_LIGAND_ID":"7011","SECONDARY_CAS_RN":"1467052-75-0","MESH_SUPPLEMENTAL_RECORD_UI":"C000593333"},"formularyStatus":[],"originalProduct":{"form":"TABLET, FILM COATED","route":"ORAL","company":"Epizyme, Inc.","brandName":"TAZVERIK","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2020-","companyName":"Epizyme Inc","relationship":"Original Developer"},{"period":"2021","companyName":"EISAI Co., Ltd.","relationship":"PMDA Licensee"}],"pharmacokinetics":{"source":"FDA label","halfLife":"3.1 hours"},"publicationCount":283,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01XX72","allCodes":["L01XX72"]},"biosimilarFilings":[],"originalDeveloper":"Epizyme Inc","recentPublications":[{"date":"2026 Mar 13","pmid":"41898517","title":"Biological Evaluation of a Novel Compound with Predicted EZH2 and EED Binding Against Human Malignant Melanoma Cells.","journal":"International journal of molecular sciences"},{"date":"2026 Mar 25","pmid":"41882006","title":"Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study.","journal":"Nature communications"},{"date":"2026 Mar 24","pmid":"41874585","title":"Epithelioid sarcoma: from SMARCB1 loss to therapeutic vulnerabilities.","journal":"Current opinion in oncology"},{"date":"2026 Feb 15","pmid":"41744650","title":"EZH2 Inhibition Restores Tumor Suppressor SFRP1 Activity by Reprogramming Extrachromosomal Circular DNA Dynamics in Ovarian Cancer.","journal":"Biology"},{"date":"2026 Feb","pmid":"41736412","title":"Therapeutic Horizons in Targeting EZH2 With Dual and Non-PROTAC Inhibitor Molecules: Recent Achievements, Comparative Analysis, and Future Perspectives.","journal":"Archiv der Pharmazie"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"active","companyName":"Epizyme Inc","companyId":"epizyme-inc","modality":"Small molecule","firstApprovalDate":"2020","enrichmentLevel":4,"visitCount":3,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-11-16T00:00:00.000Z","mah":"EPIZYME INC","brand_name_local":null,"application_number":"NDA211723"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":4,"withResults":3},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:54:31.496347+00:00","fieldsConflicting":12,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}